This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-let-7a-5p | AIFM1 | -0.33 | 0.00046 | -0.39 | 0.00049 | TargetScan; miRNATAP | -0.16 | 0.00689 | NA | |
2 | hsa-let-7b-5p | AIFM1 | -0.96 | 0 | -0.39 | 0.00049 | miRNATAP | -0.09 | 0.0139 | NA | |
3 | hsa-let-7d-5p | AIFM1 | 0.05 | 0.70258 | -0.39 | 0.00049 | miRNATAP | -0.23 | 0 | NA | |
4 | hsa-let-7e-5p | AIFM1 | 0.04 | 0.81107 | -0.39 | 0.00049 | miRNATAP | -0.27 | 0 | NA | |
5 | hsa-let-7i-5p | AIFM1 | -0.14 | 0.15414 | -0.39 | 0.00049 | miRNATAP | -0.27 | 0 | NA | |
6 | hsa-miR-125a-5p | AIFM1 | -0.91 | 0 | -0.39 | 0.00049 | miRanda | -0.14 | 0 | NA | |
7 | hsa-miR-155-5p | AIFM1 | 0.01 | 0.95651 | -0.39 | 0.00049 | miRNAWalker2 validate | -0.09 | 0.00127 | NA | |
8 | hsa-miR-20a-3p | AIFM1 | -0.32 | 0.04679 | -0.39 | 0.00049 | miRNATAP | -0.11 | 0.00067 | NA | |
9 | hsa-miR-425-5p | AIFM1 | 0.59 | 2.0E-5 | -0.39 | 0.00049 | miRNATAP | -0.15 | 8.0E-5 | NA | |
10 | hsa-miR-429 | AIFM1 | -1.4 | 7.0E-5 | -0.39 | 0.00049 | miRNATAP | -0.09 | 0 | NA | |
11 | hsa-miR-125a-5p | AKT2 | -0.91 | 0 | -0.34 | 1.0E-5 | mirMAP | -0.05 | 0.0142 | NA | |
12 | hsa-miR-149-5p | AKT2 | -0.32 | 0.18721 | -0.34 | 1.0E-5 | miRNAWalker2 validate | -0.08 | 0 | NA | |
13 | hsa-miR-183-5p | AKT2 | 2.33 | 0 | -0.34 | 1.0E-5 | mirMAP | -0.06 | 0 | NA | |
14 | hsa-miR-1976 | AKT2 | -0.43 | 0.00325 | -0.34 | 1.0E-5 | miRNATAP | -0.05 | 0.04381 | NA | |
15 | hsa-miR-21-5p | AKT2 | 1.51 | 0 | -0.34 | 1.0E-5 | miRNAWalker2 validate | -0.25 | 0 | NA | |
16 | hsa-miR-330-5p | AKT2 | 0.44 | 0.00533 | -0.34 | 1.0E-5 | miRanda | -0.1 | 1.0E-5 | NA | |
17 | hsa-miR-338-3p | AKT2 | 0.54 | 0.00461 | -0.34 | 1.0E-5 | mirMAP | -0.09 | 0 | NA | |
18 | hsa-miR-342-3p | AKT2 | -0.32 | 0.04498 | -0.34 | 1.0E-5 | mirMAP | -0.12 | 0 | NA | |
19 | hsa-miR-671-5p | AKT2 | 0.84 | 0 | -0.34 | 1.0E-5 | miRNATAP | -0.06 | 0.01107 | NA | |
20 | hsa-miR-766-3p | AKT2 | 0.2 | 0.25723 | -0.34 | 1.0E-5 | mirMAP | -0.06 | 0.00542 | NA | |
21 | hsa-miR-106b-5p | AKT3 | 0.65 | 0 | -0.66 | 0.00047 | miRNATAP | -0.26 | 0.00148 | NA | |
22 | hsa-miR-107 | AKT3 | 0.24 | 0.01708 | -0.66 | 0.00047 | PITA; miRanda | -0.6 | 0 | NA | |
23 | hsa-miR-122-5p | AKT3 | -1.24 | 0 | -0.66 | 0.00047 | miRNAWalker2 validate; miRTarBase | -0.28 | 0 | 24244539 | miR 122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3; Here we identify AKT3 as a novel and direct target of miR-122; Restoration of miR-122 expression in HCC cell lines decreases AKT3 levels inhibits cell migration and proliferation and induces apoptosis; These anti-tumor phenotypes can be rescued by reconstitution of AKT3 expression indicating the essential role of AKT3 in miR-122 mediated HCC transformation; Our data strongly suggest that miR-122 is a tumor suppressor that targets AKT3 to regulate tumorigenesis in HCCs and a potential therapeutic candidate for liver cancer |
24 | hsa-miR-146b-5p | AKT3 | 0.42 | 0.04574 | -0.66 | 0.00047 | miRNAWalker2 validate | -0.16 | 0.00026 | NA | |
25 | hsa-miR-15a-5p | AKT3 | 0.35 | 0.00077 | -0.66 | 0.00047 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.27 | 0.00291 | NA | |
26 | hsa-miR-17-3p | AKT3 | 0.41 | 0.00422 | -0.66 | 0.00047 | miRNATAP | -0.35 | 0 | NA | |
27 | hsa-miR-17-5p | AKT3 | 0.7 | 2.0E-5 | -0.66 | 0.00047 | TargetScan; miRNATAP | -0.29 | 0 | NA | |
28 | hsa-miR-20a-5p | AKT3 | 0.85 | 0 | -0.66 | 0.00047 | miRNATAP | -0.29 | 0 | NA | |
29 | hsa-miR-32-3p | AKT3 | 0.22 | 0.20722 | -0.66 | 0.00047 | mirMAP | -0.23 | 4.0E-5 | NA | |
30 | hsa-miR-33a-3p | AKT3 | -0.68 | 1.0E-5 | -0.66 | 0.00047 | mirMAP | -0.23 | 0.0001 | NA | |
31 | hsa-miR-362-3p | AKT3 | 0.81 | 0 | -0.66 | 0.00047 | miRanda | -0.22 | 0.00083 | NA | |
32 | hsa-miR-362-5p | AKT3 | 0.72 | 2.0E-5 | -0.66 | 0.00047 | PITA; TargetScan; miRNATAP | -0.15 | 0.00734 | NA | |
33 | hsa-miR-374a-5p | AKT3 | 0.02 | 0.86978 | -0.66 | 0.00047 | mirMAP | -0.28 | 0.00294 | NA | |
34 | hsa-miR-421 | AKT3 | 0.94 | 0 | -0.66 | 0.00047 | miRanda; mirMAP | -0.13 | 0.01091 | NA | |
35 | hsa-miR-501-3p | AKT3 | 1 | 0 | -0.66 | 0.00047 | miRNATAP | -0.12 | 0.04823 | NA | |
36 | hsa-miR-502-3p | AKT3 | 0.66 | 0 | -0.66 | 0.00047 | miRNATAP | -0.26 | 0.0008 | NA | |
37 | hsa-miR-616-5p | AKT3 | 0.15 | 0.40284 | -0.66 | 0.00047 | mirMAP | -0.2 | 0.0001 | NA | |
38 | hsa-miR-93-5p | AKT3 | 1.4 | 0 | -0.66 | 0.00047 | miRNATAP | -0.28 | 1.0E-5 | NA | |
39 | hsa-miR-139-5p | APAF1 | -2.11 | 0 | 0.22 | 0.0143 | mirMAP | -0.1 | 1.0E-5 | NA | |
40 | hsa-miR-3607-3p | APAF1 | -2.16 | 0 | 0.22 | 0.0143 | mirMAP; miRNATAP | -0.07 | 0.00025 | NA | |
41 | hsa-miR-30d-3p | ATM | -0.12 | 0.32955 | -0.24 | 0.01738 | mirMAP | -0.14 | 0.00043 | 24345332 | miR-30d has been observed to be significantly down-regulated in human anaplastic thyroid carcinoma ATC and is believed to be an important event in thyroid cell transformation; In this study we found that miR-30d has a critical role in modulating sensitivity of ATC cells to cisplatin a commonly used chemotherapeutic drug for treatment of this neoplasm; Using a mimic of miR-30d we demonstrated that miR-30d could negatively regulate the expression of beclin 1 a key autophagy gene leading to suppression of the cisplatin-activated autophagic response that protects ATC cells from apoptosis; We further showed that inhibition of the beclin 1-mediated autophagy by the miR-30d mimic sensitized ATC cells to cisplatin both in vitro cell culture and in vivo animal xenograft model; These results suggest that dysregulation of miR-30d in ATC cells is responsible for the insensitivity to cisplatin by promoting autophagic survival; Thus miR-30d may be exploited as a potential target for therapeutic intervention in the treatment of ATC |
42 | hsa-miR-30d-5p | ATM | 0.72 | 0 | -0.24 | 0.01738 | mirMAP | -0.08 | 0.03814 | 24345332 | miR-30d has been observed to be significantly down-regulated in human anaplastic thyroid carcinoma ATC and is believed to be an important event in thyroid cell transformation; In this study we found that miR-30d has a critical role in modulating sensitivity of ATC cells to cisplatin a commonly used chemotherapeutic drug for treatment of this neoplasm; Using a mimic of miR-30d we demonstrated that miR-30d could negatively regulate the expression of beclin 1 a key autophagy gene leading to suppression of the cisplatin-activated autophagic response that protects ATC cells from apoptosis; We further showed that inhibition of the beclin 1-mediated autophagy by the miR-30d mimic sensitized ATC cells to cisplatin both in vitro cell culture and in vivo animal xenograft model; These results suggest that dysregulation of miR-30d in ATC cells is responsible for the insensitivity to cisplatin by promoting autophagic survival; Thus miR-30d may be exploited as a potential target for therapeutic intervention in the treatment of ATC |
43 | hsa-miR-324-5p | ATM | 0.37 | 0.00592 | -0.24 | 0.01738 | miRanda | -0.09 | 0.009 | NA | |
44 | hsa-miR-339-5p | ATM | 0.28 | 0.03557 | -0.24 | 0.01738 | miRanda | -0.1 | 0.00399 | NA | |
45 | hsa-miR-455-5p | ATM | -0.27 | 0.05813 | -0.24 | 0.01738 | miRanda | -0.12 | 0.00045 | NA | |
46 | hsa-miR-127-3p | BAD | -1.08 | 2.0E-5 | 0.07 | 0.50941 | miRanda; miRNATAP | -0.07 | 0.00096 | NA | |
47 | hsa-miR-122-5p | BAX | -1.24 | 0 | 0.8 | 0 | miRNAWalker2 validate | -0.09 | 0 | NA | |
48 | hsa-miR-30a-5p | BAX | -0.63 | 0.00011 | 0.8 | 0 | miRNAWalker2 validate | -0.12 | 0.00058 | NA | |
49 | hsa-miR-365a-3p | BAX | 0.16 | 0.15325 | 0.8 | 0 | miRNAWalker2 validate | -0.23 | 0 | 24216611 | MiR 365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro apoptotic regulator BAX |
50 | hsa-miR-103a-3p | BCL2 | 0.77 | 0 | -0.35 | 0.02497 | miRNAWalker2 validate | -0.28 | 4.0E-5 | NA | |
51 | hsa-miR-130b-5p | BCL2 | 0.17 | 0.33761 | -0.35 | 0.02497 | mirMAP | -0.17 | 7.0E-5 | 27364335 | The level of microRNA-130b in relationship with the expression of PPARĪ³ VEGF-A BCL-2 and apoptosis were analyzed in 91 lung cancer patient samples using immunohistochemistry and terminal deoxynucleotidyl transferase dUTP nick end labeling TUNEL assay on tissue microarrays; In vitro and in vivo miR-130b enrichment associated with down-regulation of PPARĪ³ up-regulation of VEGF-A and BCL-2 and decreased apoptosis |
52 | hsa-miR-148a-3p | BCL2 | -0.75 | 0 | -0.35 | 0.02497 | miRNAWalker2 validate; miRTarBase | -0.31 | 0 | 21455217; 23975374 | MiR 148a promotes apoptosis by targeting Bcl 2 in colorectal cancer;MiR 148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl 2; Using western blot and luciferase activity assay CCKBR and Bcl-2 were identified as targets of miR-148a; Moreover we also found that the expression of Bcl-2 lacking in 3'UTR could abrogate the pro-apoptosis function of miR-148a |
53 | hsa-miR-15a-5p | BCL2 | 0.35 | 0.00077 | -0.35 | 0.02497 | miRNAWalker2 validate; miRTarBase | -0.17 | 0.02172 | 25594541; 26915294; 18931683; 25623762; 22335947 | MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MicroRNAs miRNAs are noncoding small RNAs that repress protein translation by targeting specific messenger RNAs miR-15a and miR-16-1 act as putative tumor suppressors by targeting the oncogene BCL2;miR 15a and miR 16 modulate drug resistance by targeting bcl 2 in human colon cancer cells; To investigate the reversal effect of targeted modulation of bcl-2 expression by miR-15a and miR-16 on drug resistance of human colon cancer cells;The expression of MiR-15a was significantly inhibited by Bcl-2 P < 0.05 |
54 | hsa-miR-15b-3p | BCL2 | 0.24 | 0.09977 | -0.35 | 0.02497 | mirMAP | -0.1 | 0.04638 | 26884837; 25594541; 26915294; 18449891 | MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2 |
55 | hsa-miR-17-5p | BCL2 | 0.7 | 2.0E-5 | -0.35 | 0.02497 | miRNAWalker2 validate; miRTarBase | -0.31 | 0 | 25435430 | Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2 |
56 | hsa-miR-186-5p | BCL2 | -0.06 | 0.53529 | -0.35 | 0.02497 | mirMAP | -0.25 | 0.00125 | NA | |
57 | hsa-miR-192-5p | BCL2 | -0.5 | 0.00345 | -0.35 | 0.02497 | miRNAWalker2 validate | -0.34 | 0 | 26550150 | MicroRNA 192 regulates chemo resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl 2; In this paper we try to test whether miR-192 regulates chemo-resistance in human carcinoma A549 mice model by targeting Bcl-2; MTT assay real-time RT-PCR western blotting assay were used to investigate miR-192 expression levels cell viability ratio and Bcl-2 protein expression levels; Bcl-2 mRNA and protein expression levels up-regulated in miR-192 inhibitor treated tumor; Bcl-2 is a key regulator for miR-192 related chemotherapy resistance; In this study we demonstrate that miR-192 regulates chemoresistance for gemcitabine and cisplatin combined chemotherapy in human adenocarcinoma lung cancer A549 cells and Bcl-2 is the target of miR-192 |
58 | hsa-miR-204-5p | BCL2 | -0.54 | 0.03309 | -0.35 | 0.02497 | miRNAWalker2 validate; miRTarBase | -0.08 | 0.00496 | 25652855; 23152059; 26191195; 27519795; 25209181 | The expressions of Bcl-2 and Sirt1 in the lower miR-204 level group were both higher than those in the higher miR-204 level group; Correlation analysis showed that miR-204 expression was negatively correlated with Bcl-2 and Sirt1 protein expression levels; Over-expressed miR-204 in SMMC-7721 cells suppressed cell proliferation and promoted cell apoptosis and down-regulated mRNA and protein expressions of both Bcl-2 and Sirt1; miR-204 could inhibit HCC cell proliferation and induce apoptosis by down-regulating the expressions of Bcl-2 and Sirt1;miR 204 targets Bcl 2 expression and enhances responsiveness of gastric cancer; Downregulation of miR-204 has prognostic value and correlates with increased staining of Bcl-2 protein in tumoral specimens; miR-204 targeted Bcl-2 messenger RNA and increased responsiveness of GC cells to 5-fluorouracil and oxaliplatin treatment; Ectopic expression of Bcl-2 protein counteracted miR-204 pro-apoptotic activity in response to 5-fluorouracil; Altogether these findings suggest that modulation of aberrant expression of miR-204 which in turn releases oncogenic Bcl-2 protein activity might hold promise for preventive and therapeutic strategies of GC;Moreover the level of miR-204 is negatively correlated with p-STAT3 and anti-apoptotic genes BCl-2 and surviving in breast cancer;Human miR-204-5p potentially targeting BCL2 has been reported to be downregulated in various cancers; We hypothesized that miR-204-5p overexpression induces cancer cell apoptosis by repressing BCL2 expression; Luciferase reporter assays were performed to verify the function of mature miR-204-5p and its direct binding to BCL2 transcripts; Human miR-204-5p targets BCL2 in PCa cells; Restoration of miR-204-5p in PCa could therefore be considered as a novel strategy by targeting antiapoptotic BCL2;This may be explained by the fact that miR-204-5p increases in colorectal cancer cases in order to inhibit increased activity of LC3B-II in autophagy and Bcl2 against apoptosis posttranscriptionally and to take role as tumor suppressor |
59 | hsa-miR-20a-3p | BCL2 | -0.32 | 0.04679 | -0.35 | 0.02497 | mirMAP | -0.24 | 0 | NA | |
60 | hsa-miR-20a-5p | BCL2 | 0.85 | 0 | -0.35 | 0.02497 | miRNAWalker2 validate; miRTarBase | -0.31 | 0 | NA | |
61 | hsa-miR-32-3p | BCL2 | 0.22 | 0.20722 | -0.35 | 0.02497 | mirMAP | -0.2 | 1.0E-5 | NA | |
62 | hsa-miR-33a-5p | BCL2 | -0.77 | 1.0E-5 | -0.35 | 0.02497 | mirMAP | -0.11 | 0.01041 | NA | |
63 | hsa-miR-34a-5p | BCL2 | 1.04 | 0 | -0.35 | 0.02497 | miRNAWalker2 validate; miRTarBase | -0.11 | 0.03329 | 23862748; 24565525; 23155233; 24444609; 20687223; 22623155; 24988056; 18803879; 19714243; 25053345; 20433755; 21399894; 22964582 | MicroRNA 34a targets Bcl 2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment; HCC tissues with lower miR-34a expression displayed higher expression of Bcl-2 protein than those with high expression of miR-34a; therefore an inverse correlation is evident between the miR-34a level and Bcl-2 expression; Bioinformatics and luciferase reporter assays revealed that miR-34a binds the 3'-UTR of the Bcl-2 mRNA and represses its translation; Western blotting analysis and qRT-PCR confirmed that Bcl-2 is inhibited by miR-34a overexpression; Functional analyses indicated that the restoration of miR-34a reduced cell viability promoted cell apoptosis and potentiated sorafenib-induced apoptosis and toxicity in HCC cell lines by inhibiting Bcl-2 expression;InĀ vitro and inĀ vivo experiments showed that miR-34a and DOX can be efficiently encapsulated into HA-CS NPs and delivered into tumor cells or tumor tissues and enhance anti-tumor effects of DOX by suppressing the expression of non-pump resistance and anti-apoptosis proto-oncogene Bcl-2;The miR-34a expression levels in cells after irradiation at 30 and 60 Gy were 0.17- and 18.7-times the BCL2 and caspase-9 expression levels respectively;Functional analyses further indicate that restoration of miR-34a inhibits B cell lymphoma-2 Bcl-2 protein expression to withdraw the survival advantage of these resistant NSCLC cells;Thus in PC3PR cells reduced expression of miR-34a confers paclitaxel resistance via up-regulating SIRT1 and Bcl2 expression; MiR-34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone-refractory prostate cancer;MiR 34a inhibits proliferation and migration of breast cancer through down regulation of Bcl 2 and SIRT1; In this study we aimed to determine the effect of miR-34a on the growth of breast cancer and to investigate whether its effect is achieved by targeting Bcl-2 and SIRT1; Bcl-2 and SIRT1 as the targets of miR-34a were found to be in reverse correlation with ectopic expression of miR-34a;Target analysis indicated that micro RNA miR-34a directly regulates Bcl-2 and miR-34a overexpression decreased Bcl-2 protein level in gastric cancer cells; We also found that luteolin upregulates miR-34a expression and downregulates Bcl-2 expression; Based on these results we can draw the conclusion that luteolin partly decreases Bcl-2 expression through upregulating miR-34a expression;miR-34 targets Notch HMGA2 and Bcl-2 genes involved in the self-renewal and survival of cancer stem cells; Human gastric cancer cells were transfected with miR-34 mimics or infected with the lentiviral miR-34-MIF expression system and validated by miR-34 reporter assay using Bcl-2 3'UTR reporter; Human gastric cancer Kato III cells with miR-34 restoration reduced the expression of target genes Bcl-2 Notch and HMGA2; Bcl-2 3'UTR reporter assay showed that the transfected miR-34s were functional and confirmed that Bcl-2 is a direct target of miR-34; The mechanism of miR-34-mediated suppression of self-renewal appears to be related to the direct modulation of downstream targets Bcl-2 Notch and HMGA2 indicating that miR-34 may be involved in gastric cancer stem cell self-renewal/differentiation decision-making;Among the target proteins regulated by miR-34 are Notch pathway proteins and Bcl-2 suggesting the possibility of a role for miR-34 in the maintenance and survival of cancer stem cells; Our data support the view that miR-34 may be involved in pancreatic cancer stem cell self-renewal potentially via the direct modulation of downstream targets Bcl-2 and Notch implying that miR-34 may play an important role in pancreatic cancer stem cell self-renewal and/or cell fate determination;Manipulating miR-34a in prostate cancer cells confirms that this miRNA regulates BCL-2 and may in part regulate response to docetaxel;For instance miR-34a up-regulation corresponded with a down-regulation of BCL2 protein; Treating Par-4-overexpressing HT29 cells with a miR-34a antagomir functionally reversed both BCL2 down-regulation and apoptosis by 5-FU;Quantitative PCR and western analysis confirmed decreased expression of two genes BCL-2 and CCND1 in docetaxel-resistant cells which are both targeted by miR-34a;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2 |
64 | hsa-miR-365a-3p | BCL2 | 0.16 | 0.15325 | -0.35 | 0.02497 | miRNAWalker2 validate; miRTarBase | -0.33 | 0 | NA | |
65 | hsa-miR-374a-5p | BCL2 | 0.02 | 0.86978 | -0.35 | 0.02497 | mirMAP | -0.18 | 0.02111 | NA | |
66 | hsa-miR-455-5p | BCL2 | -0.27 | 0.05813 | -0.35 | 0.02497 | mirMAP | -0.19 | 0.00037 | NA | |
67 | hsa-miR-590-5p | BCL2 | -0.1 | 0.31003 | -0.35 | 0.02497 | miRanda | -0.29 | 0.00011 | NA | |
68 | hsa-miR-616-5p | BCL2 | 0.15 | 0.40284 | -0.35 | 0.02497 | mirMAP | -0.28 | 0 | NA | |
69 | hsa-miR-618 | BCL2 | 0.14 | 0.51715 | -0.35 | 0.02497 | mirMAP | -0.21 | 0 | NA | |
70 | hsa-miR-142-3p | BCL2L1 | -1.42 | 0 | 0.02 | 0.82745 | miRNATAP | -0.09 | 0.00098 | NA | |
71 | hsa-miR-149-5p | BCL2L1 | -0.32 | 0.18721 | 0.02 | 0.82745 | mirMAP | -0.05 | 0.01088 | NA | |
72 | hsa-miR-326 | BCL2L1 | -1.88 | 0 | 0.02 | 0.82745 | PITA; miRanda; mirMAP; miRNATAP | -0.09 | 0.00045 | NA | |
73 | hsa-miR-330-5p | BCL2L1 | 0.44 | 0.00533 | 0.02 | 0.82745 | PITA; miRanda; miRNATAP | -0.15 | 0 | NA | |
74 | hsa-miR-342-3p | BCL2L1 | -0.32 | 0.04498 | 0.02 | 0.82745 | PITA; miRanda; miRNATAP | -0.12 | 8.0E-5 | NA | |
75 | hsa-miR-342-5p | BCL2L1 | -0.78 | 0 | 0.02 | 0.82745 | miRNATAP | -0.11 | 0.00084 | NA | |
76 | hsa-miR-484 | BCL2L1 | 0.09 | 0.45398 | 0.02 | 0.82745 | miRNAWalker2 validate | -0.21 | 0 | NA | |
77 | hsa-miR-491-5p | BCL2L1 | -0.37 | 0.0154 | 0.02 | 0.82745 | miRNAWalker2 validate; miRTarBase; MirTarget; miRanda | -0.08 | 0.01586 | 25299770; 20039318; 23519249 | We found that miR-491-5p efficiently induces apoptosis in IGROV1-R10 cells by directly inhibiting BCL-XL expression and by inducing BIM accumulation in its dephosphorylated form;Functional screening identifies a microRNA miR 491 that induces apoptosis by targeting Bcl XL in colorectal cancer cells; We demonstrated that Bcl-XL was a direct target of miR-491 and its silencing contributed to miR-491-induced apoptosis; Our study provides a new regulation of Bcl-XL by miR-491 in colorectal cancer cells and suggests a therapeutic potential of miRNAs for treating colorectal cancer by targeting Bcl-XL;Targeted site prediction indicated that both Bcl-XL and TP53 contain miR-491-5p recognizing sites in their 3' UTRs; Overexpression of miR-491-5p in the pancreatic cancer cell line SW1990 effectively inhibited both endogenous Bcl-XL and TP53 gene expressions |
78 | hsa-miR-940 | BCL2L1 | 0.45 | 0.01771 | 0.02 | 0.82745 | mirMAP | -0.08 | 0.00373 | NA | |
79 | hsa-miR-140-5p | BID | -0.22 | 0.01407 | 0.21 | 0.07516 | miRanda | -0.21 | 0.00101 | NA | |
80 | hsa-miR-29b-3p | BIRC2 | -0.35 | 0.01214 | -0.32 | 0 | MirTarget | -0.06 | 0.00892 | NA | |
81 | hsa-miR-330-3p | BIRC2 | -0.33 | 0.03161 | -0.32 | 0 | miRNATAP | -0.06 | 0.00998 | NA | |
82 | hsa-miR-500a-5p | BIRC2 | 0.8 | 0 | -0.32 | 0 | MirTarget | -0.07 | 0.00137 | NA | |
83 | hsa-miR-24-1-5p | BIRC3 | -1.32 | 0 | 0.35 | 0.15976 | MirTarget | -0.3 | 0.0004 | NA | |
84 | hsa-miR-26b-5p | BIRC3 | -1.11 | 0 | 0.35 | 0.15976 | mirMAP | -0.35 | 0.00041 | NA | |
85 | hsa-miR-374a-5p | BIRC3 | 0.02 | 0.86978 | 0.35 | 0.15976 | mirMAP | -0.56 | 0 | NA | |
86 | hsa-miR-374b-5p | BIRC3 | -0.31 | 0.00301 | 0.35 | 0.15976 | mirMAP | -0.3 | 0.0093 | NA | |
87 | hsa-miR-616-3p | BIRC3 | -0.7 | 2.0E-5 | 0.35 | 0.15976 | MirTarget | -0.15 | 0.046 | NA | |
88 | hsa-miR-651-5p | BIRC3 | -0.24 | 0.08175 | 0.35 | 0.15976 | MirTarget | -0.28 | 0.00126 | NA | |
89 | hsa-miR-664a-3p | BIRC3 | 0.49 | 0.00073 | 0.35 | 0.15976 | mirMAP | -0.27 | 0.00118 | NA | |
90 | hsa-miR-140-5p | CAPN1 | -0.22 | 0.01407 | 0.2 | 0.01338 | miRanda; miRNATAP | -0.15 | 0.00087 | NA | |
91 | hsa-miR-101-3p | CAPN2 | -1.48 | 0 | 0.66 | 0 | miRNAWalker2 validate; MirTarget | -0.21 | 0 | NA | |
92 | hsa-miR-107 | CAPN2 | 0.24 | 0.01708 | 0.66 | 0 | miRanda | -0.2 | 0.00125 | NA | |
93 | hsa-miR-1468-5p | CAPN2 | -1.21 | 0 | 0.66 | 0 | MirTarget | -0.1 | 0.00079 | NA | |
94 | hsa-miR-16-2-3p | CAPN2 | -0.03 | 0.80516 | 0.66 | 0 | mirMAP | -0.15 | 0.0006 | NA | |
95 | hsa-miR-20a-3p | CAPN2 | -0.32 | 0.04679 | 0.66 | 0 | MirTarget | -0.13 | 0.00067 | NA | |
96 | hsa-miR-299-5p | CAPN2 | -1.29 | 0 | 0.66 | 0 | MirTarget | -0.06 | 0.01237 | NA | |
97 | hsa-miR-33a-3p | CAPN2 | -0.68 | 1.0E-5 | 0.66 | 0 | mirMAP | -0.13 | 0.00096 | NA | |
98 | hsa-miR-421 | CAPN2 | 0.94 | 0 | 0.66 | 0 | miRanda | -0.07 | 0.03811 | NA | |
99 | hsa-miR-548j-5p | CAPN2 | 0.25 | 0.17136 | 0.66 | 0 | MirTarget | -0.07 | 0.04097 | NA | |
100 | hsa-miR-590-3p | CAPN2 | -0.47 | 2.0E-5 | 0.66 | 0 | miRanda | -0.22 | 5.0E-5 | NA | |
101 | hsa-miR-590-5p | CAPN2 | -0.1 | 0.31003 | 0.66 | 0 | miRanda | -0.24 | 5.0E-5 | NA | |
102 | hsa-miR-30b-3p | CASP10 | -0.44 | 0.00095 | -0.16 | 0.06144 | MirTarget | -0.07 | 0.02213 | NA | |
103 | hsa-let-7g-5p | CASP3 | -0.46 | 2.0E-5 | 0.31 | 0.00047 | MirTarget; miRNATAP | -0.11 | 0.00694 | NA | |
104 | hsa-miR-101-3p | CASP3 | -1.48 | 0 | 0.31 | 0.00047 | MirTarget | -0.09 | 0.00599 | NA | |
105 | hsa-miR-139-5p | CASP3 | -2.11 | 0 | 0.31 | 0.00047 | miRanda | -0.07 | 0.0008 | NA | |
106 | hsa-miR-140-5p | CASP3 | -0.22 | 0.01407 | 0.31 | 0.00047 | miRanda | -0.1 | 0.03228 | NA | |
107 | hsa-miR-30a-5p | CASP3 | -0.63 | 0.00011 | 0.31 | 0.00047 | miRNATAP | -0.07 | 0.00479 | NA | |
108 | hsa-miR-374b-5p | CASP3 | -0.31 | 0.00301 | 0.31 | 0.00047 | mirMAP | -0.14 | 0.00058 | NA | |
109 | hsa-miR-106b-5p | CASP7 | 0.65 | 0 | -0.72 | 0 | miRNAWalker2 validate | -0.09 | 0.04918 | 22986525 | MicroRNA 106b 25 cluster expression is associated with early disease recurrence and targets caspase 7 and focal adhesion in human prostate cancer; Moreover increased tumor miR-106b expression was associated with disease recurrence and the combination of high miR-106b and low CASP7 caspase-7 expressions in primary tumors was an independent predictor of early disease recurrence adjusted hazard ratio=4.1; 95% confidence interval: 1.6-12.3; The approach revealed that CASP7 is a direct target of miR-106b which was confirmed by western blot analysis and a 3'-untranslated region reporter assay; Moreover selected phenotypes induced by miR-106b knockdown in DU145 human prostate cancer cells did not develop when both miR-106b and CASP7 expression were inhibited |
110 | hsa-miR-664a-3p | CASP7 | 0.49 | 0.00073 | -0.72 | 0 | MirTarget | -0.1 | 0.00545 | NA | |
111 | hsa-miR-107 | CASP8 | 0.24 | 0.01708 | 0.33 | 0.00029 | miRanda | -0.11 | 0.01137 | NA | |
112 | hsa-miR-143-3p | CASP8 | -0.58 | 0.00091 | 0.33 | 0.00029 | MirTarget | -0.05 | 0.03237 | NA | |
113 | hsa-miR-26b-5p | CASP8 | -1.11 | 0 | 0.33 | 0.00029 | miRNAWalker2 validate | -0.09 | 0.02018 | NA | |
114 | hsa-miR-455-5p | CASP8 | -0.27 | 0.05813 | 0.33 | 0.00029 | miRanda | -0.15 | 0 | NA | |
115 | hsa-miR-542-3p | CASP8 | -1.31 | 0 | 0.33 | 0.00029 | miRanda | -0.13 | 4.0E-5 | NA | |
116 | hsa-miR-17-5p | CASP9 | 0.7 | 2.0E-5 | -0.17 | 0.12115 | TargetScan | -0.08 | 0.00899 | NA | |
117 | hsa-miR-199a-3p | CASP9 | -2.33 | 0 | -0.17 | 0.12115 | mirMAP | -0.05 | 0.00586 | 23319430 | The techniques used were the MTT assay flow cytometry real-time PCR to assess miR-199a expression as also caspase-8 and caspase-9 activity in HepG2 cells treated with Propofol |
118 | hsa-miR-199b-3p | CASP9 | -2.33 | 0 | -0.17 | 0.12115 | mirMAP | -0.05 | 0.00585 | NA | |
119 | hsa-miR-222-5p | CASP9 | 0.13 | 0.48742 | -0.17 | 0.12115 | mirMAP | -0.09 | 0.00171 | NA | |
120 | hsa-miR-103a-2-5p | CFLAR | 1.17 | 0 | -0.33 | 0 | mirMAP | -0.06 | 0.00057 | NA | |
121 | hsa-miR-107 | CFLAR | 0.24 | 0.01708 | -0.33 | 0 | miRanda | -0.15 | 1.0E-5 | NA | |
122 | hsa-miR-130b-3p | CFLAR | 0.69 | 0.00011 | -0.33 | 0 | mirMAP | -0.05 | 0.00441 | NA | |
123 | hsa-miR-301a-3p | CFLAR | 0.84 | 0 | -0.33 | 0 | mirMAP | -0.06 | 0.00213 | NA | |
124 | hsa-miR-339-5p | CFLAR | 0.28 | 0.03557 | -0.33 | 0 | miRanda | -0.08 | 0.0011 | NA | |
125 | hsa-miR-455-5p | CFLAR | -0.27 | 0.05813 | -0.33 | 0 | miRanda | -0.11 | 0 | NA | |
126 | hsa-miR-660-5p | CFLAR | 0.99 | 0 | -0.33 | 0 | mirMAP | -0.13 | 0 | NA | |
127 | hsa-miR-582-5p | CHP2 | -0.68 | 0.00104 | 0.85 | 0.03429 | miRNATAP | -0.22 | 0.02359 | NA | |
128 | hsa-miR-15a-5p | CHUK | 0.35 | 0.00077 | -0.2 | 0.00863 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.12 | 0.00057 | NA | |
129 | hsa-miR-15b-5p | CHUK | 0.23 | 0.08248 | -0.2 | 0.00863 | MirTarget | -0.12 | 2.0E-5 | NA | |
130 | hsa-miR-16-5p | CHUK | -0.4 | 0.0001 | -0.2 | 0.00863 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.15 | 3.0E-5 | NA | |
131 | hsa-miR-23a-3p | CHUK | -0.18 | 0.13598 | -0.2 | 0.00863 | MirTarget | -0.1 | 0.00114 | NA | |
132 | hsa-miR-29b-2-5p | CHUK | -0.22 | 0.08431 | -0.2 | 0.00863 | MirTarget | -0.07 | 0.02235 | NA | |
133 | hsa-miR-339-5p | CHUK | 0.28 | 0.03557 | -0.2 | 0.00863 | miRanda | -0.12 | 1.0E-5 | NA | |
134 | hsa-miR-342-3p | CHUK | -0.32 | 0.04498 | -0.2 | 0.00863 | miRanda | -0.06 | 0.00622 | NA | |
135 | hsa-miR-497-5p | CHUK | -1.41 | 0 | -0.2 | 0.00863 | MirTarget | -0.05 | 0.01421 | NA | |
136 | hsa-miR-590-5p | CHUK | -0.1 | 0.31003 | -0.2 | 0.00863 | miRanda | -0.12 | 0.00129 | NA | |
137 | hsa-miR-19a-3p | CSF2RB | 1.02 | 0 | -0.51 | 0.00683 | MirTarget | -0.12 | 0.00885 | NA | |
138 | hsa-miR-19b-3p | CSF2RB | 0.6 | 0.00017 | -0.51 | 0.00683 | MirTarget | -0.15 | 0.00713 | NA | |
139 | hsa-miR-204-5p | CSF2RB | -0.54 | 0.03309 | -0.51 | 0.00683 | MirTarget | -0.11 | 0.00224 | NA | |
140 | hsa-miR-30b-3p | CSF2RB | -0.44 | 0.00095 | -0.51 | 0.00683 | MirTarget | -0.2 | 0.00366 | NA | |
141 | hsa-miR-455-5p | CSF2RB | -0.27 | 0.05813 | -0.51 | 0.00683 | miRanda | -0.37 | 0 | NA | |
142 | hsa-miR-532-5p | CSF2RB | 1.03 | 0 | -0.51 | 0.00683 | MirTarget | -0.33 | 0 | NA | |
143 | hsa-miR-139-5p | CYCS | -2.11 | 0 | 0.26 | 0.01519 | miRanda | -0.06 | 0.02282 | NA | |
144 | hsa-miR-148a-3p | CYCS | -0.75 | 0 | 0.26 | 0.01519 | miRNAWalker2 validate | -0.08 | 0.022 | NA | |
145 | hsa-miR-361-5p | CYCS | 0.23 | 0.00962 | 0.26 | 0.01519 | miRNAWalker2 validate | -0.17 | 0.00331 | NA | |
146 | hsa-let-7b-5p | DFFA | -0.96 | 0 | 0.07 | 0.4191 | miRNAWalker2 validate | -0.11 | 8.0E-5 | NA | |
147 | hsa-miR-145-5p | DFFA | -1.48 | 0 | 0.07 | 0.4191 | miRNAWalker2 validate; miRTarBase | -0.06 | 0.00558 | NA | |
148 | hsa-miR-200b-3p | DFFA | -1.29 | 0.00027 | 0.07 | 0.4191 | TargetScan; mirMAP | -0.05 | 1.0E-5 | NA | |
149 | hsa-miR-26a-2-3p | DFFA | -0.55 | 8.0E-5 | 0.07 | 0.4191 | mirMAP | -0.06 | 0.03461 | NA | |
150 | hsa-miR-26a-5p | DFFA | -0.96 | 0 | 0.07 | 0.4191 | mirMAP | -0.16 | 4.0E-5 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 50 | 1929 | 2.144e-35 | 9.974e-32 |
2 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 22 | 99 | 1.115e-34 | 2.593e-31 |
3 | INTRACELLULAR SIGNAL TRANSDUCTION | 46 | 1572 | 4.543e-34 | 7.046e-31 |
4 | APOPTOTIC SIGNALING PATHWAY | 28 | 289 | 1.295e-33 | 1.507e-30 |
5 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 21 | 95 | 4.875e-33 | 4.537e-30 |
6 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 17 | 39 | 1.039e-32 | 8.059e-30 |
7 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 25 | 213 | 4.851e-32 | 3.224e-29 |
8 | ZYMOGEN ACTIVATION | 21 | 112 | 2.191e-31 | 1.274e-28 |
9 | CELL DEATH | 38 | 1001 | 3.583e-31 | 1.852e-28 |
10 | REGULATION OF CELL DEATH | 42 | 1472 | 5.437e-30 | 2.53e-27 |
11 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 42 | 1492 | 9.38e-30 | 3.968e-27 |
12 | POSITIVE REGULATION OF CELL COMMUNICATION | 42 | 1532 | 2.728e-29 | 1.058e-26 |
13 | POSITIVE REGULATION OF PEPTIDASE ACTIVITY | 21 | 154 | 2.823e-28 | 1.01e-25 |
14 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 43 | 1791 | 8.886e-28 | 2.757e-25 |
15 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 34 | 876 | 8.397e-28 | 2.757e-25 |
16 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 43 | 1848 | 3.198e-27 | 9.299e-25 |
17 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 41 | 1656 | 1.027e-26 | 2.81e-24 |
18 | PROTEIN MATURATION | 23 | 265 | 2.537e-26 | 6.558e-24 |
19 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 11 | 13 | 3.281e-26 | 8.035e-24 |
20 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 39 | 1518 | 9.463e-26 | 2.202e-23 |
21 | REGULATION OF PEPTIDASE ACTIVITY | 25 | 392 | 2.722e-25 | 6.031e-23 |
22 | POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 20 | 179 | 4.034e-25 | 8.533e-23 |
23 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 37 | 1381 | 7.613e-25 | 1.54e-22 |
24 | POSITIVE REGULATION OF CELL DEATH | 28 | 605 | 1.329e-24 | 2.576e-22 |
25 | POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 11 | 17 | 5.15e-24 | 9.584e-22 |
26 | NEGATIVE REGULATION OF CELL DEATH | 31 | 872 | 5.598e-24 | 1.002e-21 |
27 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 19 | 171 | 7.982e-24 | 1.376e-21 |
28 | REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 20 | 233 | 8.988e-23 | 1.494e-20 |
29 | REGULATION OF PROTEOLYSIS | 28 | 711 | 1.076e-22 | 1.727e-20 |
30 | RESPONSE TO CYTOKINE | 28 | 714 | 1.206e-22 | 1.87e-20 |
31 | IMMUNE SYSTEM PROCESS | 40 | 1984 | 1.407e-22 | 2.111e-20 |
32 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 11 | 22 | 2.896e-22 | 4.211e-20 |
33 | REGULATION OF IMMUNE SYSTEM PROCESS | 34 | 1403 | 3.65e-21 | 5.147e-19 |
34 | REGULATION OF IMMUNE RESPONSE | 28 | 858 | 1.672e-20 | 2.288e-18 |
35 | POSITIVE REGULATION OF PROTEOLYSIS | 21 | 363 | 2.631e-20 | 3.401e-18 |
36 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 21 | 363 | 2.631e-20 | 3.401e-18 |
37 | ACTIVATION OF IMMUNE RESPONSE | 22 | 427 | 3.453e-20 | 4.343e-18 |
38 | POSITIVE REGULATION OF IMMUNE RESPONSE | 24 | 563 | 3.966e-20 | 4.856e-18 |
39 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 16 | 153 | 1.074e-19 | 1.281e-17 |
40 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 11 | 34 | 1.137e-19 | 1.322e-17 |
41 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 14 | 98 | 2.704e-19 | 3.069e-17 |
42 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 29 | 1135 | 2.214e-18 | 2.453e-16 |
43 | REGULATION OF TRANSFERASE ACTIVITY | 27 | 946 | 3.015e-18 | 3.262e-16 |
44 | RESPONSE TO NITROGEN COMPOUND | 26 | 859 | 3.658e-18 | 3.869e-16 |
45 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 15 | 152 | 4.061e-18 | 4.199e-16 |
46 | REGULATION OF KINASE ACTIVITY | 25 | 776 | 4.448e-18 | 4.499e-16 |
47 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 26 | 867 | 4.59e-18 | 4.544e-16 |
48 | I KAPPAB KINASE NF KAPPAB SIGNALING | 12 | 70 | 1.137e-17 | 1.102e-15 |
49 | NEURON APOPTOTIC PROCESS | 10 | 35 | 2.416e-17 | 2.294e-15 |
50 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 27 | 1036 | 2.98e-17 | 2.719e-15 |
51 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 27 | 1036 | 2.98e-17 | 2.719e-15 |
52 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 32 | 1618 | 3.54e-17 | 3.167e-15 |
53 | CYTOKINE MEDIATED SIGNALING PATHWAY | 20 | 452 | 4.555e-17 | 3.925e-15 |
54 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 11 | 55 | 4.491e-17 | 3.925e-15 |
55 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 22 | 606 | 5.914e-17 | 5.003e-15 |
56 | REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 14 | 144 | 7.23e-17 | 5.902e-15 |
57 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 17 | 279 | 7.149e-17 | 5.902e-15 |
58 | RESPONSE TO TUMOR NECROSIS FACTOR | 16 | 233 | 9.739e-17 | 7.813e-15 |
59 | PROTEOLYSIS | 28 | 1208 | 1.307e-16 | 1.03e-14 |
60 | TOLL LIKE RECEPTOR SIGNALING PATHWAY | 12 | 85 | 1.35e-16 | 1.047e-14 |
61 | REGULATION OF HYDROLASE ACTIVITY | 29 | 1327 | 1.449e-16 | 1.105e-14 |
62 | POSITIVE REGULATION OF KINASE ACTIVITY | 20 | 482 | 1.573e-16 | 1.18e-14 |
63 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 25 | 905 | 1.645e-16 | 1.215e-14 |
64 | RESPONSE TO ABIOTIC STIMULUS | 26 | 1024 | 2.603e-16 | 1.876e-14 |
65 | NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 15 | 200 | 2.621e-16 | 1.876e-14 |
66 | ACTIVATION OF INNATE IMMUNE RESPONSE | 15 | 204 | 3.529e-16 | 2.488e-14 |
67 | NEURON DEATH | 10 | 47 | 6.594e-16 | 4.555e-14 |
68 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 16 | 263 | 6.657e-16 | 4.555e-14 |
69 | REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 10 | 50 | 1.297e-15 | 8.749e-14 |
70 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 23 | 799 | 1.517e-15 | 9.939e-14 |
71 | RESPONSE TO ENDOGENOUS STIMULUS | 29 | 1450 | 1.499e-15 | 9.939e-14 |
72 | REGULATION OF PROTEIN MODIFICATION PROCESS | 31 | 1710 | 1.579e-15 | 1.02e-13 |
73 | PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 12 | 109 | 3.014e-15 | 1.921e-13 |
74 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 15 | 246 | 5.75e-15 | 3.616e-13 |
75 | POSITIVE REGULATION OF DEFENSE RESPONSE | 17 | 364 | 5.96e-15 | 3.698e-13 |
76 | TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 12 | 118 | 8.011e-15 | 4.905e-13 |
77 | RESPONSE TO BIOTIC STIMULUS | 23 | 886 | 1.376e-14 | 8.314e-13 |
78 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 20 | 616 | 1.673e-14 | 9.979e-13 |
79 | REGULATION OF RESPONSE TO STRESS | 28 | 1468 | 1.849e-14 | 1.089e-12 |
80 | PHOSPHORYLATION | 26 | 1228 | 1.96e-14 | 1.14e-12 |
81 | REGULATION OF NECROTIC CELL DEATH | 8 | 26 | 2.213e-14 | 1.271e-12 |
82 | NECROTIC CELL DEATH | 8 | 28 | 4.379e-14 | 2.485e-12 |
83 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 10 | 71 | 5.506e-14 | 3.087e-12 |
84 | REGULATION OF INNATE IMMUNE RESPONSE | 16 | 357 | 7.863e-14 | 4.355e-12 |
85 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 31 | 1977 | 8.472e-14 | 4.638e-12 |
86 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 18 | 505 | 8.893e-14 | 4.812e-12 |
87 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 16 | 370 | 1.364e-13 | 7.295e-12 |
88 | REGULATION OF NEURON DEATH | 14 | 252 | 1.827e-13 | 9.662e-12 |
89 | SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 8 | 33 | 1.929e-13 | 9.865e-12 |
90 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 8 | 33 | 1.929e-13 | 9.865e-12 |
91 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 10 | 80 | 1.916e-13 | 9.865e-12 |
92 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 15 | 321 | 2.839e-13 | 1.436e-11 |
93 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 15 | 323 | 3.106e-13 | 1.554e-11 |
94 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 17 | 470 | 3.824e-13 | 1.893e-11 |
95 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 8 | 36 | 4.17e-13 | 2.043e-11 |
96 | PROTEIN PHOSPHORYLATION | 22 | 944 | 5.227e-13 | 2.533e-11 |
97 | CELLULAR RESPONSE TO STRESS | 27 | 1565 | 7.164e-13 | 3.436e-11 |
98 | POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 11 | 132 | 1.054e-12 | 5.004e-11 |
99 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 15 | 360 | 1.485e-12 | 6.978e-11 |
100 | RESPONSE TO HORMONE | 21 | 893 | 1.696e-12 | 7.89e-11 |
101 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 8 | 43 | 1.96e-12 | 9.031e-11 |
102 | REGULATION OF MEMBRANE PERMEABILITY | 9 | 70 | 2.539e-12 | 1.158e-10 |
103 | RESPONSE TO EXTERNAL STIMULUS | 28 | 1821 | 3.74e-12 | 1.689e-10 |
104 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 13 | 264 | 6.682e-12 | 2.99e-10 |
105 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 29 | 6.94e-12 | 3.047e-10 |
106 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 29 | 6.94e-12 | 3.047e-10 |
107 | REGULATION OF DEFENSE RESPONSE | 19 | 759 | 8.326e-12 | 3.621e-10 |
108 | MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 7 | 30 | 9.028e-12 | 3.889e-10 |
109 | NIK NF KAPPAB SIGNALING | 9 | 83 | 1.238e-11 | 5.285e-10 |
110 | REGULATION OF CELL PROLIFERATION | 25 | 1496 | 1.392e-11 | 5.887e-10 |
111 | RESPONSE TO LIPID | 20 | 888 | 1.416e-11 | 5.937e-10 |
112 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 12 | 228 | 2.142e-11 | 8.9e-10 |
113 | RESPONSE TO BACTERIUM | 16 | 528 | 2.96e-11 | 1.219e-09 |
114 | MITOCHONDRIAL MEMBRANE ORGANIZATION | 9 | 92 | 3.192e-11 | 1.303e-09 |
115 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 16 | 552 | 5.721e-11 | 2.315e-09 |
116 | REGULATION OF NEURON APOPTOTIC PROCESS | 11 | 192 | 6.327e-11 | 2.538e-09 |
117 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 10 | 142 | 6.522e-11 | 2.594e-09 |
118 | NECROPTOTIC PROCESS | 6 | 21 | 7.687e-11 | 3.031e-09 |
119 | POSITIVE REGULATION OF NEURON DEATH | 8 | 67 | 8.251e-11 | 3.226e-09 |
120 | REGULATION OF EXECUTION PHASE OF APOPTOSIS | 6 | 24 | 1.891e-10 | 7.332e-09 |
121 | REGULATION OF NECROPTOTIC PROCESS | 5 | 11 | 2.064e-10 | 7.937e-09 |
122 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 15 | 514 | 2.264e-10 | 8.636e-09 |
123 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 7 | 47 | 2.661e-10 | 1.007e-08 |
124 | REGULATION OF INTRACELLULAR TRANSPORT | 16 | 621 | 3.226e-10 | 1.21e-08 |
125 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 7 | 49 | 3.614e-10 | 1.345e-08 |
126 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 9 | 121 | 3.832e-10 | 1.415e-08 |
127 | HOMEOSTATIC PROCESS | 22 | 1337 | 4.602e-10 | 1.686e-08 |
128 | IMMUNE RESPONSE | 20 | 1100 | 6.308e-10 | 2.291e-08 |
129 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 22 | 1360 | 6.35e-10 | 2.291e-08 |
130 | POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 7 | 53 | 6.415e-10 | 2.296e-08 |
131 | EXECUTION PHASE OF APOPTOSIS | 7 | 55 | 8.398e-10 | 2.983e-08 |
132 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 19 | 1008 | 1.033e-09 | 3.64e-08 |
133 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 6 | 32 | 1.245e-09 | 4.357e-08 |
134 | T CELL APOPTOTIC PROCESS | 5 | 15 | 1.327e-09 | 4.608e-08 |
135 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 10 | 195 | 1.471e-09 | 5.07e-08 |
136 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 18 | 917 | 1.654e-09 | 5.658e-08 |
137 | T CELL HOMEOSTASIS | 6 | 34 | 1.838e-09 | 6.244e-08 |
138 | POSITIVE REGULATION OF GENE EXPRESSION | 24 | 1733 | 1.908e-09 | 6.432e-08 |
139 | FC RECEPTOR SIGNALING PATHWAY | 10 | 206 | 2.502e-09 | 8.377e-08 |
140 | NEGATIVE REGULATION OF CELL COMMUNICATION | 20 | 1192 | 2.532e-09 | 8.415e-08 |
141 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 8 | 103 | 2.723e-09 | 8.923e-08 |
142 | ACTIVATION OF PROTEIN KINASE A ACTIVITY | 5 | 17 | 2.72e-09 | 8.923e-08 |
143 | CELLULAR RESPONSE TO PEPTIDE | 11 | 274 | 2.764e-09 | 8.993e-08 |
144 | RESPONSE TO MECHANICAL STIMULUS | 10 | 210 | 3.013e-09 | 9.735e-08 |
145 | PROTEIN OLIGOMERIZATION | 13 | 434 | 3.056e-09 | 9.805e-08 |
146 | REGULATION OF CATABOLIC PROCESS | 16 | 731 | 3.388e-09 | 1.08e-07 |
147 | LYMPHOCYTE APOPTOTIC PROCESS | 5 | 18 | 3.756e-09 | 1.189e-07 |
148 | REGULATION OF MITOCHONDRION ORGANIZATION | 10 | 218 | 4.319e-09 | 1.358e-07 |
149 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 12 | 365 | 4.686e-09 | 1.463e-07 |
150 | INFLAMMATORY RESPONSE | 13 | 454 | 5.243e-09 | 1.626e-07 |
151 | RESPONSE TO AMINO ACID | 8 | 112 | 5.312e-09 | 1.637e-07 |
152 | LEUKOCYTE DIFFERENTIATION | 11 | 292 | 5.366e-09 | 1.643e-07 |
153 | CHEMICAL HOMEOSTASIS | 17 | 874 | 5.891e-09 | 1.784e-07 |
154 | CELLULAR RESPONSE TO HORMONE STIMULUS | 14 | 552 | 5.903e-09 | 1.784e-07 |
155 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 9 | 167 | 6.682e-09 | 2.006e-07 |
156 | PROTEIN COMPLEX BIOGENESIS | 19 | 1132 | 6.965e-09 | 2.064e-07 |
157 | PROTEIN COMPLEX ASSEMBLY | 19 | 1132 | 6.965e-09 | 2.064e-07 |
158 | CELLULAR GLUCOSE HOMEOSTASIS | 7 | 75 | 7.773e-09 | 2.289e-07 |
159 | CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS | 6 | 43 | 8.13e-09 | 2.379e-07 |
160 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 8 | 120 | 9.182e-09 | 2.67e-07 |
161 | REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 6 | 44 | 9.388e-09 | 2.713e-07 |
162 | RESPONSE TO INORGANIC SUBSTANCE | 13 | 479 | 9.931e-09 | 2.852e-07 |
163 | RESPONSE TO OXYGEN LEVELS | 11 | 311 | 1.031e-08 | 2.944e-07 |
164 | MITOCHONDRIAL TRANSPORT | 9 | 177 | 1.111e-08 | 3.152e-07 |
165 | RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 5 | 22 | 1.142e-08 | 3.22e-07 |
166 | IMMUNE SYSTEM DEVELOPMENT | 14 | 582 | 1.153e-08 | 3.232e-07 |
167 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 6 | 46 | 1.239e-08 | 3.452e-07 |
168 | REGULATION OF ORGANELLE ORGANIZATION | 19 | 1178 | 1.329e-08 | 3.68e-07 |
169 | REGULATION OF MAP KINASE ACTIVITY | 11 | 319 | 1.34e-08 | 3.69e-07 |
170 | RESPONSE TO PEPTIDE | 12 | 404 | 1.451e-08 | 3.96e-07 |
171 | LEUKOCYTE APOPTOTIC PROCESS | 5 | 23 | 1.455e-08 | 3.96e-07 |
172 | POSITIVE REGULATION OF TRANSPORT | 17 | 936 | 1.625e-08 | 4.396e-07 |
173 | REGULATION OF PROTEIN LOCALIZATION | 17 | 950 | 2.021e-08 | 5.435e-07 |
174 | LYMPHOCYTE HOMEOSTASIS | 6 | 50 | 2.079e-08 | 5.559e-07 |
175 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 18 | 1079 | 2.092e-08 | 5.562e-07 |
176 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 10 | 258 | 2.156e-08 | 5.699e-07 |
177 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 25 | 2.285e-08 | 6.007e-07 |
178 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 6 | 51 | 2.349e-08 | 6.141e-07 |
179 | POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 6 | 52 | 2.649e-08 | 6.885e-07 |
180 | RESPONSE TO OXIDATIVE STRESS | 11 | 352 | 3.677e-08 | 9.505e-07 |
181 | NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY | 5 | 28 | 4.193e-08 | 1.072e-06 |
182 | POSITIVE REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 5 | 28 | 4.193e-08 | 1.072e-06 |
183 | T CELL RECEPTOR SIGNALING PATHWAY | 8 | 146 | 4.284e-08 | 1.089e-06 |
184 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 11 | 4.457e-08 | 1.127e-06 |
185 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 10 | 282 | 4.987e-08 | 1.254e-06 |
186 | POSITIVE REGULATION OF NIK NF KAPPAB SIGNALING | 5 | 29 | 5.053e-08 | 1.264e-06 |
187 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 10 | 289 | 6.276e-08 | 1.562e-06 |
188 | LEUKOCYTE HOMEOSTASIS | 6 | 60 | 6.372e-08 | 1.577e-06 |
189 | RESPONSE TO WOUNDING | 13 | 563 | 6.632e-08 | 1.633e-06 |
190 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 4 | 12 | 6.667e-08 | 1.633e-06 |
191 | RENAL SYSTEM PROCESS | 7 | 102 | 6.713e-08 | 1.635e-06 |
192 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 9 | 220 | 7.278e-08 | 1.764e-06 |
193 | CELL ACTIVATION | 13 | 568 | 7.35e-08 | 1.772e-06 |
194 | POSITIVE REGULATION OF PROTEIN IMPORT | 7 | 104 | 7.679e-08 | 1.842e-06 |
195 | MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 5 | 32 | 8.499e-08 | 2.028e-06 |
196 | INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 4 | 13 | 9.605e-08 | 2.269e-06 |
197 | RESPONSE TO COBALT ION | 4 | 13 | 9.605e-08 | 2.269e-06 |
198 | CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 5 | 33 | 9.989e-08 | 2.347e-06 |
199 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 22 | 1805 | 1.121e-07 | 2.621e-06 |
200 | RENAL WATER HOMEOSTASIS | 5 | 34 | 1.168e-07 | 2.717e-06 |
201 | RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 9 | 233 | 1.188e-07 | 2.751e-06 |
202 | MITOCHONDRION ORGANIZATION | 13 | 594 | 1.233e-07 | 2.841e-06 |
203 | RESPONSE TO CARBOHYDRATE | 8 | 168 | 1.272e-07 | 2.915e-06 |
204 | TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 4 | 14 | 1.341e-07 | 3.059e-06 |
205 | PROTEIN HETEROOLIGOMERIZATION | 7 | 113 | 1.362e-07 | 3.091e-06 |
206 | GLUCOSE HOMEOSTASIS | 8 | 170 | 1.393e-07 | 3.131e-06 |
207 | CARBOHYDRATE HOMEOSTASIS | 8 | 170 | 1.393e-07 | 3.131e-06 |
208 | RESPONSE TO INTERLEUKIN 1 | 7 | 115 | 1.536e-07 | 3.437e-06 |
209 | RESPONSE TO TOXIC SUBSTANCE | 9 | 241 | 1.583e-07 | 3.525e-06 |
210 | PROTEIN COMPLEX SUBUNIT ORGANIZATION | 20 | 1527 | 1.595e-07 | 3.533e-06 |
211 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 14 | 720 | 1.616e-07 | 3.563e-06 |
212 | RESPONSE TO CORTICOSTEROID | 8 | 176 | 1.819e-07 | 3.992e-06 |
213 | MACROMOLECULAR COMPLEX ASSEMBLY | 19 | 1398 | 2.004e-07 | 4.377e-06 |
214 | CELLULAR RESPONSE TO GLUCAGON STIMULUS | 5 | 38 | 2.084e-07 | 4.532e-06 |
215 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 6 | 74 | 2.269e-07 | 4.91e-06 |
216 | RESPONSE TO METAL ION | 10 | 333 | 2.343e-07 | 5.046e-06 |
217 | LEUKOCYTE CELL CELL ADHESION | 9 | 255 | 2.553e-07 | 5.475e-06 |
218 | INOSITOL LIPID MEDIATED SIGNALING | 7 | 124 | 2.575e-07 | 5.496e-06 |
219 | REGULATION OF CELLULAR LOCALIZATION | 18 | 1277 | 2.66e-07 | 5.651e-06 |
220 | LYMPHOCYTE ACTIVATION | 10 | 342 | 2.995e-07 | 6.333e-06 |
221 | REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 17 | 3.164e-07 | 6.601e-06 |
222 | ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY | 4 | 17 | 3.164e-07 | 6.601e-06 |
223 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 4 | 17 | 3.164e-07 | 6.601e-06 |
224 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 7 | 128 | 3.198e-07 | 6.643e-06 |
225 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 7 | 129 | 3.372e-07 | 6.974e-06 |
226 | RESPONSE TO REACTIVE OXYGEN SPECIES | 8 | 191 | 3.4e-07 | 7.001e-06 |
227 | REGULATION OF NIK NF KAPPAB SIGNALING | 5 | 42 | 3.494e-07 | 7.162e-06 |
228 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 8 | 193 | 3.681e-07 | 7.513e-06 |
229 | JNK CASCADE | 6 | 82 | 4.195e-07 | 8.524e-06 |
230 | RESPONSE TO ALCOHOL | 10 | 362 | 5.04e-07 | 1.02e-05 |
231 | RESPONSE TO ALKALOID | 7 | 137 | 5.076e-07 | 1.022e-05 |
232 | REGULATION OF TRANSPORT | 21 | 1804 | 5.159e-07 | 1.035e-05 |
233 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 8 | 207 | 6.264e-07 | 1.251e-05 |
234 | CELLULAR RESPONSE TO INTERLEUKIN 1 | 6 | 88 | 6.387e-07 | 1.259e-05 |
235 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 12 | 573 | 6.377e-07 | 1.259e-05 |
236 | NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 6 | 88 | 6.387e-07 | 1.259e-05 |
237 | POSITIVE REGULATION OF MAPK CASCADE | 11 | 470 | 6.663e-07 | 1.303e-05 |
238 | WOUND HEALING | 11 | 470 | 6.663e-07 | 1.303e-05 |
239 | LYMPHOCYTE DIFFERENTIATION | 8 | 209 | 6.737e-07 | 1.312e-05 |
240 | RESPONSE TO GLUCAGON | 5 | 48 | 6.92e-07 | 1.342e-05 |
241 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 8 | 211 | 7.239e-07 | 1.398e-05 |
242 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 10 | 381 | 8.029e-07 | 1.544e-05 |
243 | DEFENSE RESPONSE | 17 | 1231 | 8.201e-07 | 1.57e-05 |
244 | REGULATION OF CYTOPLASMIC TRANSPORT | 11 | 481 | 8.361e-07 | 1.594e-05 |
245 | RESPONSE TO GAMMA RADIATION | 5 | 50 | 8.516e-07 | 1.617e-05 |
246 | PEPTIDYL SERINE MODIFICATION | 7 | 148 | 8.555e-07 | 1.618e-05 |
247 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 14 | 829 | 8.824e-07 | 1.662e-05 |
248 | REGULATION OF CELL ACTIVATION | 11 | 484 | 8.886e-07 | 1.667e-05 |
249 | RESPONSE TO NICOTINE | 5 | 51 | 9.416e-07 | 1.76e-05 |
250 | POSITIVE REGULATION OF PROTEIN OLIGOMERIZATION | 4 | 22 | 9.596e-07 | 1.786e-05 |
251 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 6 | 95 | 1.005e-06 | 1.863e-05 |
252 | POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 23 | 1.159e-06 | 2.139e-05 |
253 | LIPID PHOSPHORYLATION | 6 | 99 | 1.281e-06 | 2.357e-05 |
254 | HEMOSTASIS | 9 | 311 | 1.34e-06 | 2.455e-05 |
255 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 10 | 404 | 1.364e-06 | 2.488e-05 |
256 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 15 | 1004 | 1.57e-06 | 2.853e-05 |
257 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 8 | 235 | 1.626e-06 | 2.944e-05 |
258 | APOPTOTIC MITOCHONDRIAL CHANGES | 5 | 57 | 1.651e-06 | 2.978e-05 |
259 | LEUKOCYTE ACTIVATION | 10 | 414 | 1.699e-06 | 3.04e-05 |
260 | REGULATION OF CELL ADHESION | 12 | 629 | 1.693e-06 | 3.04e-05 |
261 | MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS | 5 | 58 | 1.802e-06 | 3.213e-05 |
262 | REGULATION OF GLUCOSE IMPORT | 5 | 60 | 2.137e-06 | 3.794e-05 |
263 | NEGATIVE REGULATION OF NEURON DEATH | 7 | 171 | 2.251e-06 | 3.982e-05 |
264 | DNA CATABOLIC PROCESS | 4 | 27 | 2.272e-06 | 4.005e-05 |
265 | RESPONSE TO VIRUS | 8 | 247 | 2.357e-06 | 4.139e-05 |
266 | RESPONSE TO DRUG | 10 | 431 | 2.434e-06 | 4.258e-05 |
267 | REGULATION OF AUTOPHAGY | 8 | 249 | 2.503e-06 | 4.361e-05 |
268 | REGULATION OF MAPK CASCADE | 12 | 660 | 2.785e-06 | 4.836e-05 |
269 | REGULATION OF PROTEIN IMPORT | 7 | 183 | 3.529e-06 | 6.105e-05 |
270 | CELLULAR HOMEOSTASIS | 12 | 676 | 3.563e-06 | 6.139e-05 |
271 | REGULATION OF CYTOKINE PRODUCTION | 11 | 563 | 3.836e-06 | 6.586e-05 |
272 | AGING | 8 | 264 | 3.859e-06 | 6.601e-05 |
273 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 15 | 1087 | 4.171e-06 | 7.108e-05 |
274 | SINGLE ORGANISM CELL ADHESION | 10 | 459 | 4.256e-06 | 7.228e-05 |
275 | CELLULAR CHEMICAL HOMEOSTASIS | 11 | 570 | 4.316e-06 | 7.303e-05 |
276 | MYELOID CELL DIFFERENTIATION | 7 | 189 | 4.367e-06 | 7.362e-05 |
277 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 4 | 32 | 4.595e-06 | 7.686e-05 |
278 | WATER HOMEOSTASIS | 5 | 70 | 4.608e-06 | 7.686e-05 |
279 | NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 4 | 32 | 4.595e-06 | 7.686e-05 |
280 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 14 | 957 | 4.734e-06 | 7.866e-05 |
281 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 10 | 465 | 4.773e-06 | 7.904e-05 |
282 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 8 | 272 | 4.808e-06 | 7.932e-05 |
283 | RESPONSE TO UV | 6 | 126 | 5.23e-06 | 8.599e-05 |
284 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 9 | 372 | 5.786e-06 | 9.48e-05 |
285 | CELLULAR RESPONSE TO ALKALOID | 4 | 34 | 5.894e-06 | 9.623e-05 |
286 | REGULATION OF LIPID METABOLIC PROCESS | 8 | 282 | 6.266e-06 | 0.0001019 |
287 | REGULATION OF PROTEIN OLIGOMERIZATION | 4 | 35 | 6.637e-06 | 0.0001073 |
288 | NEGATIVE REGULATION OF NECROTIC CELL DEATH | 3 | 11 | 6.64e-06 | 0.0001073 |
289 | B CELL ACTIVATION | 6 | 132 | 6.839e-06 | 0.0001101 |
290 | REGULATION OF CELL CELL ADHESION | 9 | 380 | 6.869e-06 | 0.0001102 |
291 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 15 | 1152 | 8.416e-06 | 0.0001344 |
292 | CELLULAR RESPONSE TO RADIATION | 6 | 137 | 8.468e-06 | 0.0001344 |
293 | REGULATION OF INFLAMMATORY RESPONSE | 8 | 294 | 8.494e-06 | 0.0001344 |
294 | ACTIVATION OF MAPK ACTIVITY | 6 | 137 | 8.468e-06 | 0.0001344 |
295 | RESPONSE TO STEROID HORMONE | 10 | 497 | 8.556e-06 | 0.0001349 |
296 | INSULIN RECEPTOR SIGNALING PATHWAY | 5 | 80 | 8.909e-06 | 0.00014 |
297 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 8 | 297 | 9.146e-06 | 0.0001433 |
298 | REGULATION OF PROTEIN MATURATION | 5 | 82 | 1.006e-05 | 0.000157 |
299 | CELLULAR RESPONSE TO OXYGEN LEVELS | 6 | 143 | 1.082e-05 | 0.0001684 |
300 | REGULATION OF CELL DIFFERENTIATION | 17 | 1492 | 1.103e-05 | 0.0001711 |
301 | RESPONSE TO ESTROGEN | 7 | 218 | 1.112e-05 | 0.0001713 |
302 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 7 | 218 | 1.112e-05 | 0.0001713 |
303 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 4 | 40 | 1.143e-05 | 0.0001747 |
304 | HEPATOCYTE APOPTOTIC PROCESS | 3 | 13 | 1.145e-05 | 0.0001747 |
305 | POSITIVE REGULATION OF MACROPHAGE DIFFERENTIATION | 3 | 13 | 1.145e-05 | 0.0001747 |
306 | REGULATION OF HOMOTYPIC CELL CELL ADHESION | 8 | 307 | 1.163e-05 | 0.0001763 |
307 | REGULATION OF PROTEIN TARGETING | 8 | 307 | 1.163e-05 | 0.0001763 |
308 | RESPONSE TO IONIZING RADIATION | 6 | 145 | 1.172e-05 | 0.0001764 |
309 | REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 6 | 145 | 1.172e-05 | 0.0001764 |
310 | RESPONSE TO ESTRADIOL | 6 | 146 | 1.219e-05 | 0.0001829 |
311 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 18 | 1672 | 1.245e-05 | 0.0001863 |
312 | RESPONSE TO RADIATION | 9 | 413 | 1.337e-05 | 0.0001994 |
313 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 4 | 42 | 1.393e-05 | 0.0002071 |
314 | REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 14 | 1.454e-05 | 0.0002154 |
315 | EPITHELIAL CELL PROLIFERATION | 5 | 89 | 1.501e-05 | 0.0002218 |
316 | RESPONSE TO ACID CHEMICAL | 8 | 319 | 1.534e-05 | 0.0002252 |
317 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 6 | 152 | 1.533e-05 | 0.0002252 |
318 | REGULATION OF LEUKOCYTE DIFFERENTIATION | 7 | 232 | 1.663e-05 | 0.0002434 |
319 | APOPTOTIC DNA FRAGMENTATION | 3 | 15 | 1.813e-05 | 0.0002644 |
320 | NEGATIVE REGULATION OF CELL CYCLE | 9 | 433 | 1.944e-05 | 0.0002826 |
321 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 16 | 1395 | 1.956e-05 | 0.0002835 |
322 | SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE | 5 | 96 | 2.169e-05 | 0.0003135 |
323 | REGULATION OF CELL CYCLE | 13 | 949 | 2.185e-05 | 0.0003146 |
324 | RESPONSE TO ANTIBIOTIC | 4 | 47 | 2.191e-05 | 0.0003146 |
325 | POSITIVE REGULATION OF CELL CELL ADHESION | 7 | 243 | 2.241e-05 | 0.0003208 |
326 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 6 | 163 | 2.277e-05 | 0.000325 |
327 | REGULATION OF LIPID KINASE ACTIVITY | 4 | 48 | 2.383e-05 | 0.0003381 |
328 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 11 | 684 | 2.382e-05 | 0.0003381 |
329 | REGULATION OF GLUCOSE TRANSPORT | 5 | 100 | 2.643e-05 | 0.0003738 |
330 | NEGATIVE REGULATION OF ANOIKIS | 3 | 17 | 2.696e-05 | 0.0003801 |
331 | POSITIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 50 | 2.806e-05 | 0.0003945 |
332 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 18 | 1784 | 2.994e-05 | 0.0004196 |
333 | POSITIVE REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY | 3 | 18 | 3.227e-05 | 0.0004495 |
334 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 3 | 18 | 3.227e-05 | 0.0004495 |
335 | GLYCEROLIPID METABOLIC PROCESS | 8 | 356 | 3.363e-05 | 0.0004665 |
336 | LEUKOCYTE MIGRATION | 7 | 259 | 3.369e-05 | 0.0004665 |
337 | HOMEOSTASIS OF NUMBER OF CELLS | 6 | 175 | 3.396e-05 | 0.000469 |
338 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 5 | 106 | 3.501e-05 | 0.0004819 |
339 | CELLULAR RESPONSE TO AMINO ACID STIMULUS | 4 | 53 | 3.54e-05 | 0.0004859 |
340 | REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS | 4 | 54 | 3.813e-05 | 0.0005165 |
341 | NEGATIVE REGULATION OF MEIOTIC CELL CYCLE | 3 | 19 | 3.822e-05 | 0.0005165 |
342 | REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL | 4 | 54 | 3.813e-05 | 0.0005165 |
343 | REGULATION OF CELL CYCLE ARREST | 5 | 108 | 3.83e-05 | 0.0005165 |
344 | REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 5 | 108 | 3.83e-05 | 0.0005165 |
345 | DNA CATABOLIC PROCESS ENDONUCLEOLYTIC | 3 | 19 | 3.822e-05 | 0.0005165 |
346 | PHOSPHOLIPID METABOLIC PROCESS | 8 | 364 | 3.937e-05 | 0.0005294 |
347 | RESPONSE TO HYDROGEN PEROXIDE | 5 | 109 | 4.003e-05 | 0.0005368 |
348 | RESPONSE TO KETONE | 6 | 182 | 4.23e-05 | 0.0005656 |
349 | REGULATION OF MYELOID CELL DIFFERENTIATION | 6 | 183 | 4.362e-05 | 0.0005815 |
350 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 8 | 370 | 4.418e-05 | 0.0005874 |
351 | POSITIVE REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS | 3 | 20 | 4.485e-05 | 0.0005929 |
352 | REGULATION OF MACROPHAGE DIFFERENTIATION | 3 | 20 | 4.485e-05 | 0.0005929 |
353 | IMMUNE EFFECTOR PROCESS | 9 | 486 | 4.789e-05 | 0.0006313 |
354 | CELL CELL ADHESION | 10 | 608 | 4.807e-05 | 0.0006318 |
355 | B CELL HOMEOSTASIS | 3 | 21 | 5.22e-05 | 0.0006822 |
356 | RESPONSE TO NITRIC OXIDE | 3 | 21 | 5.22e-05 | 0.0006822 |
357 | PROTEIN DEPHOSPHORYLATION | 6 | 190 | 5.376e-05 | 0.0007007 |
358 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 59 | 5.415e-05 | 0.0007039 |
359 | PROTEIN AUTOPHOSPHORYLATION | 6 | 192 | 5.698e-05 | 0.0007386 |
360 | EMBRYO DEVELOPMENT | 12 | 894 | 5.748e-05 | 0.0007429 |
361 | REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 5 | 118 | 5.851e-05 | 0.0007542 |
362 | REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY INVOLVED IN APOPTOTIC PROCESS | 3 | 22 | 6.029e-05 | 0.0007728 |
363 | REGULATION OF PROTEIN HOMODIMERIZATION ACTIVITY | 3 | 22 | 6.029e-05 | 0.0007728 |
364 | MEMBRANE ORGANIZATION | 12 | 899 | 6.064e-05 | 0.0007752 |
365 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 4 | 61 | 6.177e-05 | 0.0007874 |
366 | REGULATION OF BODY FLUID LEVELS | 9 | 506 | 6.533e-05 | 0.0008306 |
367 | REGULATION OF B CELL ACTIVATION | 5 | 121 | 6.594e-05 | 0.0008361 |
368 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 5 | 122 | 6.858e-05 | 0.0008671 |
369 | T CELL DIFFERENTIATION | 5 | 123 | 7.129e-05 | 0.0008989 |
370 | NEGATIVE REGULATION OF HYDROLASE ACTIVITY | 8 | 397 | 7.241e-05 | 0.0009106 |
371 | CELLULAR COMPONENT DISASSEMBLY | 9 | 515 | 7.478e-05 | 0.0009378 |
372 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 6 | 203 | 7.757e-05 | 0.0009703 |
373 | REGULATION OF ANOIKIS | 3 | 24 | 7.884e-05 | 0.0009834 |
374 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 5 | 126 | 7.993e-05 | 0.0009944 |
375 | MACROMOLECULE CATABOLIC PROCESS | 12 | 926 | 8.048e-05 | 0.0009986 |
376 | CELLULAR RESPONSE TO UV | 4 | 66 | 8.419e-05 | 0.001042 |
377 | APOPTOTIC NUCLEAR CHANGES | 3 | 25 | 8.936e-05 | 0.0011 |
378 | EPITHELIAL CELL APOPTOTIC PROCESS | 3 | 25 | 8.936e-05 | 0.0011 |
379 | LIPID MODIFICATION | 6 | 210 | 9.35e-05 | 0.001148 |
380 | REGULATION OF RESPONSE TO WOUNDING | 8 | 413 | 9.529e-05 | 0.001167 |
381 | POSITIVE REGULATION OF LEUKOCYTE DIFFERENTIATION | 5 | 131 | 9.609e-05 | 0.001174 |
382 | INTERSPECIES INTERACTION BETWEEN ORGANISMS | 10 | 662 | 9.754e-05 | 0.001185 |
383 | SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM | 10 | 662 | 9.754e-05 | 0.001185 |
384 | CELL DEVELOPMENT | 15 | 1426 | 0.0001003 | 0.001216 |
385 | POSITIVE REGULATION OF CELL ACTIVATION | 7 | 311 | 0.0001065 | 0.001287 |
386 | CELL PROLIFERATION | 10 | 672 | 0.0001103 | 0.00133 |
387 | NEGATIVE REGULATION OF NEURON APOPTOTIC PROCESS | 5 | 135 | 0.0001107 | 0.001331 |
388 | REGULATION OF HEMOPOIESIS | 7 | 314 | 0.000113 | 0.001356 |
389 | POSITIVE REGULATION OF CELL PROLIFERATION | 11 | 814 | 0.0001143 | 0.001368 |
390 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 138 | 0.0001228 | 0.001465 |
391 | POSITIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS | 3 | 28 | 0.0001263 | 0.0015 |
392 | MODULATION BY SYMBIONT OF HOST CELLULAR PROCESS | 3 | 28 | 0.0001263 | 0.0015 |
393 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 4 | 74 | 0.0001316 | 0.001558 |
394 | REGULATION OF CELLULAR RESPONSE TO STRESS | 10 | 691 | 0.0001386 | 0.001637 |
395 | NEGATIVE REGULATION OF PROTEOLYSIS | 7 | 329 | 0.0001508 | 0.001777 |
396 | NEGATIVE REGULATION OF B CELL ACTIVATION | 3 | 30 | 0.0001558 | 0.00183 |
397 | CELLULAR RESPONSE TO INSULIN STIMULUS | 5 | 146 | 0.00016 | 0.001875 |
398 | REGULATION OF HOMEOSTATIC PROCESS | 8 | 447 | 0.0001642 | 0.001919 |
399 | REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 5 | 147 | 0.0001651 | 0.001926 |
400 | REGULATION OF LEUKOCYTE APOPTOTIC PROCESS | 4 | 79 | 0.0001696 | 0.001973 |
401 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 8 | 450 | 0.0001718 | 0.001991 |
402 | LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 3 | 31 | 0.000172 | 0.001991 |
403 | ESTABLISHMENT OF LOCALIZATION IN CELL | 16 | 1676 | 0.0001755 | 0.002027 |
404 | REGULATION OF DNA METABOLIC PROCESS | 7 | 340 | 0.0001846 | 0.002126 |
405 | POSITIVE REGULATION OF MYELOID CELL DIFFERENTIATION | 4 | 81 | 0.0001868 | 0.002146 |
406 | CELLULAR RESPONSE TO LIPID | 8 | 457 | 0.0001909 | 0.002188 |
407 | NEGATIVE REGULATION OF PEPTIDASE ACTIVITY | 6 | 245 | 0.0002165 | 0.002475 |
408 | CELLULAR RESPONSE TO INORGANIC SUBSTANCE | 5 | 156 | 0.0002178 | 0.002484 |
409 | GAMETE GENERATION | 9 | 595 | 0.0002218 | 0.002524 |
410 | POSITIVE REGULATION OF CELL CYCLE ARREST | 4 | 85 | 0.000225 | 0.002553 |
411 | PROTEIN KINASE B SIGNALING | 3 | 34 | 0.0002273 | 0.002573 |
412 | PROTEIN HOMOOLIGOMERIZATION | 6 | 248 | 0.0002311 | 0.00261 |
413 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 4 | 86 | 0.0002354 | 0.002652 |
414 | NEGATIVE REGULATION OF PROTEIN PROCESSING | 3 | 35 | 0.000248 | 0.002774 |
415 | RESPONSE TO GROWTH FACTOR | 8 | 475 | 0.000248 | 0.002774 |
416 | NEGATIVE REGULATION OF PROTEIN MATURATION | 3 | 35 | 0.000248 | 0.002774 |
417 | POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 4 | 88 | 0.0002571 | 0.002869 |
418 | POSITIVE REGULATION OF HEMOPOIESIS | 5 | 163 | 0.0002669 | 0.002971 |
419 | B CELL DIFFERENTIATION | 4 | 89 | 0.0002685 | 0.002981 |
420 | CALCIUM MEDIATED SIGNALING | 4 | 90 | 0.0002802 | 0.003105 |
421 | CELLULAR RESPONSE TO LIGHT STIMULUS | 4 | 91 | 0.0002923 | 0.00323 |
422 | MODULATION BY VIRUS OF HOST MORPHOLOGY OR PHYSIOLOGY | 3 | 37 | 0.0002929 | 0.00323 |
423 | INNATE IMMUNE RESPONSE | 9 | 619 | 0.000297 | 0.003267 |
424 | INTRACELLULAR RECEPTOR SIGNALING PATHWAY | 5 | 168 | 0.0003069 | 0.003368 |
425 | CELLULAR LIPID METABOLIC PROCESS | 11 | 913 | 0.0003097 | 0.003391 |
426 | MITOTIC CELL CYCLE | 10 | 766 | 0.0003176 | 0.003469 |
427 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 10 | 767 | 0.0003209 | 0.003497 |
428 | NEGATIVE REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 5 | 170 | 0.0003241 | 0.003523 |
429 | POSITIVE REGULATION OF CELL ADHESION | 7 | 376 | 0.0003402 | 0.003685 |
430 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 8 | 498 | 0.0003406 | 0.003685 |
431 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 3 | 39 | 0.0003428 | 0.003693 |
432 | SPLEEN DEVELOPMENT | 3 | 39 | 0.0003428 | 0.003693 |
433 | FC GAMMA RECEPTOR SIGNALING PATHWAY | 4 | 95 | 0.0003446 | 0.003703 |
434 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 11 | 926 | 0.0003493 | 0.003745 |
435 | STRIATED MUSCLE CELL DIFFERENTIATION | 5 | 173 | 0.0003512 | 0.003757 |
436 | MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 96 | 0.0003586 | 0.003827 |
437 | REGULATION OF MEIOTIC CELL CYCLE | 3 | 40 | 0.0003697 | 0.003927 |
438 | REGULATION OF ACTIVATED T CELL PROLIFERATION | 3 | 40 | 0.0003697 | 0.003927 |
439 | NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 4 | 98 | 0.0003879 | 0.004112 |
440 | MITOTIC SPINDLE ASSEMBLY | 3 | 41 | 0.0003979 | 0.004198 |
441 | MICROTUBULE CYTOSKELETON ORGANIZATION INVOLVED IN MITOSIS | 3 | 41 | 0.0003979 | 0.004198 |
442 | REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 4 | 101 | 0.000435 | 0.00458 |
443 | RESPONSE TO LIGHT STIMULUS | 6 | 280 | 0.0004417 | 0.00464 |
444 | GLAND DEVELOPMENT | 7 | 395 | 0.0004571 | 0.00479 |
445 | CELLULAR RESPONSE TO OXIDATIVE STRESS | 5 | 184 | 0.0004657 | 0.004869 |
446 | DEPHOSPHORYLATION | 6 | 286 | 0.0004941 | 0.005154 |
447 | POSITIVE REGULATION OF INTERLEUKIN 8 PRODUCTION | 3 | 45 | 0.0005244 | 0.005422 |
448 | THYMOCYTE AGGREGATION | 3 | 45 | 0.0005244 | 0.005422 |
449 | MODIFICATION BY SYMBIONT OF HOST MORPHOLOGY OR PHYSIOLOGY | 3 | 45 | 0.0005244 | 0.005422 |
450 | T CELL DIFFERENTIATION IN THYMUS | 3 | 45 | 0.0005244 | 0.005422 |
451 | LIPID BIOSYNTHETIC PROCESS | 8 | 539 | 0.000575 | 0.005933 |
452 | POSITIVE REGULATION OF PROTEIN COMPLEX ASSEMBLY | 5 | 197 | 0.0006349 | 0.006536 |
453 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 9 | 689 | 0.0006454 | 0.00663 |
454 | REGULATION OF CERAMIDE BIOSYNTHETIC PROCESS | 2 | 11 | 0.0006507 | 0.006655 |
455 | POSITIVE REGULATION OF HAIR CYCLE | 2 | 11 | 0.0006507 | 0.006655 |
456 | OVULATION CYCLE | 4 | 113 | 0.0006648 | 0.006768 |
457 | NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 5 | 199 | 0.0006646 | 0.006768 |
458 | REGULATION OF TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 49 | 0.0006741 | 0.006848 |
459 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 8 | 554 | 0.0006881 | 0.00696 |
460 | REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY | 4 | 114 | 0.0006871 | 0.00696 |
461 | REGULATION OF IMMUNE EFFECTOR PROCESS | 7 | 424 | 0.0006955 | 0.007019 |
462 | REGULATION OF CELL CYCLE PROCESS | 8 | 558 | 0.0007211 | 0.007263 |
463 | FEMALE SEX DIFFERENTIATION | 4 | 116 | 0.0007335 | 0.007371 |
464 | RESPONSE TO INSULIN | 5 | 205 | 0.0007598 | 0.007619 |
465 | REGULATION OF LEUKOCYTE PROLIFERATION | 5 | 206 | 0.0007766 | 0.007713 |
466 | REGULATION OF VITAMIN METABOLIC PROCESS | 2 | 12 | 0.0007791 | 0.007713 |
467 | REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 2 | 12 | 0.0007791 | 0.007713 |
468 | REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER | 2 | 12 | 0.0007791 | 0.007713 |
469 | REPLICATIVE SENESCENCE | 2 | 12 | 0.0007791 | 0.007713 |
470 | POSITIVE REGULATION OF EXECUTION PHASE OF APOPTOSIS | 2 | 12 | 0.0007791 | 0.007713 |
471 | HEAD DEVELOPMENT | 9 | 709 | 0.0007911 | 0.007816 |
472 | CELLULAR RESPONSE TO IONIZING RADIATION | 3 | 52 | 0.0008025 | 0.007894 |
473 | REGULATION OF T CELL MEDIATED IMMUNITY | 3 | 52 | 0.0008025 | 0.007894 |
474 | GLUCOSE METABOLIC PROCESS | 4 | 119 | 0.000807 | 0.007922 |
475 | GERM CELL DEVELOPMENT | 5 | 209 | 0.0008287 | 0.008117 |
476 | BIOLOGICAL ADHESION | 11 | 1032 | 0.0008635 | 0.00844 |
477 | NEGATIVE REGULATION OF REPRODUCTIVE PROCESS | 3 | 54 | 0.0008962 | 0.008724 |
478 | B CELL RECEPTOR SIGNALING PATHWAY | 3 | 54 | 0.0008962 | 0.008724 |
479 | REGULATION OF ADAPTIVE IMMUNE RESPONSE | 4 | 123 | 0.0009131 | 0.008814 |
480 | REGULATION OF SPHINGOLIPID BIOSYNTHETIC PROCESS | 2 | 13 | 0.0009187 | 0.008814 |
481 | REGULATION OF MEMBRANE LIPID METABOLIC PROCESS | 2 | 13 | 0.0009187 | 0.008814 |
482 | POSITIVE REGULATION OF ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE | 2 | 13 | 0.0009187 | 0.008814 |
483 | REGULATION OF PROTEIN POLYUBIQUITINATION | 2 | 13 | 0.0009187 | 0.008814 |
484 | PROTEIN AUTOPROCESSING | 2 | 13 | 0.0009187 | 0.008814 |
485 | REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 2 | 13 | 0.0009187 | 0.008814 |
486 | NEGATIVE REGULATION OF CELL CYCLE PROCESS | 5 | 214 | 0.0009212 | 0.00882 |
487 | TUBE MORPHOGENESIS | 6 | 323 | 0.0009323 | 0.008908 |
488 | REGULATION OF B CELL PROLIFERATION | 3 | 55 | 0.0009455 | 0.009016 |
489 | POSITIVE REGULATION OF HOMEOSTATIC PROCESS | 5 | 216 | 0.0009603 | 0.009138 |
490 | SEXUAL REPRODUCTION | 9 | 730 | 0.0009721 | 0.009231 |
491 | ORGANOPHOSPHATE METABOLIC PROCESS | 10 | 885 | 0.0009756 | 0.009245 |
492 | REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 5 | 217 | 0.0009803 | 0.009271 |
493 | POSITIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 3 | 57 | 0.001049 | 0.009883 |
494 | REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 3 | 57 | 0.001049 | 0.009883 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY BINDING | 13 | 47 | 4.656e-22 | 4.325e-19 |
2 | DEATH RECEPTOR BINDING | 9 | 18 | 2.19e-18 | 1.017e-15 |
3 | CYTOKINE RECEPTOR BINDING | 16 | 271 | 1.068e-15 | 3.308e-13 |
4 | ENZYME BINDING | 30 | 1737 | 2.032e-14 | 4.719e-12 |
5 | KINASE ACTIVITY | 21 | 842 | 5.503e-13 | 1.022e-10 |
6 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 13 | 264 | 6.682e-12 | 9.566e-10 |
7 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 6 | 15 | 7.208e-12 | 9.566e-10 |
8 | TUMOR NECROSIS FACTOR RECEPTOR BINDING | 7 | 30 | 9.028e-12 | 1.048e-09 |
9 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 21 | 992 | 1.241e-11 | 1.281e-09 |
10 | PROTEIN HETERODIMERIZATION ACTIVITY | 15 | 468 | 6.135e-11 | 5.699e-09 |
11 | PROTEASE BINDING | 9 | 104 | 9.768e-11 | 8.249e-09 |
12 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 8 | 70 | 1.184e-10 | 9.17e-09 |
13 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 7 | 43 | 1.379e-10 | 9.851e-09 |
14 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 14 | 445 | 3.691e-10 | 2.449e-08 |
15 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 7 | 51 | 4.845e-10 | 3e-08 |
16 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 8 | 86 | 6.369e-10 | 3.698e-08 |
17 | PROTEIN KINASE ACTIVITY | 15 | 640 | 4.536e-09 | 2.479e-07 |
18 | CYSTEINE TYPE ENDOPEPTIDASE REGULATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 6 | 42 | 7.015e-09 | 3.62e-07 |
19 | KINASE REGULATOR ACTIVITY | 9 | 186 | 1.711e-08 | 8.365e-07 |
20 | KINASE BINDING | 14 | 606 | 1.916e-08 | 8.477e-07 |
21 | DEATH RECEPTOR ACTIVITY | 5 | 24 | 1.833e-08 | 8.477e-07 |
22 | ENZYME REGULATOR ACTIVITY | 17 | 959 | 2.321e-08 | 9.799e-07 |
23 | ADENYL NUCLEOTIDE BINDING | 21 | 1514 | 2.638e-08 | 1.065e-06 |
24 | PROTEIN DIMERIZATION ACTIVITY | 18 | 1149 | 5.461e-08 | 2.114e-06 |
25 | RECEPTOR BINDING | 20 | 1476 | 9.162e-08 | 3.405e-06 |
26 | MOLECULAR FUNCTION REGULATOR | 19 | 1353 | 1.203e-07 | 4.139e-06 |
27 | IDENTICAL PROTEIN BINDING | 18 | 1209 | 1.177e-07 | 4.139e-06 |
28 | PROTEIN PHOSPHATASE BINDING | 7 | 120 | 2.058e-07 | 6.827e-06 |
29 | PROTEIN DOMAIN SPECIFIC BINDING | 13 | 624 | 2.172e-07 | 6.958e-06 |
30 | CYSTEINE TYPE PEPTIDASE ACTIVITY | 8 | 184 | 2.557e-07 | 7.918e-06 |
31 | RIBONUCLEOTIDE BINDING | 21 | 1860 | 8.536e-07 | 2.558e-05 |
32 | PHOSPHATASE BINDING | 7 | 162 | 1.569e-06 | 4.556e-05 |
33 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 4 | 30 | 3.52e-06 | 9.909e-05 |
34 | INSULIN RECEPTOR SUBSTRATE BINDING | 3 | 11 | 6.64e-06 | 0.0001814 |
35 | PEPTIDASE REGULATOR ACTIVITY | 7 | 214 | 9.855e-06 | 0.0002616 |
36 | PROTEIN KINASE A BINDING | 4 | 42 | 1.393e-05 | 0.0003594 |
37 | PROTEIN KINASE A CATALYTIC SUBUNIT BINDING | 3 | 15 | 1.813e-05 | 0.0004551 |
38 | PROTEIN COMPLEX BINDING | 13 | 935 | 1.869e-05 | 0.0004568 |
39 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 3 | 16 | 2.225e-05 | 0.0005301 |
40 | PEPTIDASE ACTIVATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 3 | 21 | 5.22e-05 | 0.001183 |
41 | ENZYME INHIBITOR ACTIVITY | 8 | 378 | 5.137e-05 | 0.001183 |
42 | CAMP BINDING | 3 | 23 | 6.915e-05 | 0.001494 |
43 | CYSTEINE TYPE ENDOPEPTIDASE INHIBITOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 3 | 23 | 6.915e-05 | 0.001494 |
44 | SIGNAL TRANSDUCER ACTIVITY | 17 | 1731 | 7.388e-05 | 0.00154 |
45 | PROTEIN SERINE THREONINE PHOSPHATASE ACTIVITY | 4 | 64 | 7.461e-05 | 0.00154 |
46 | MACROMOLECULAR COMPLEX BINDING | 15 | 1399 | 8.093e-05 | 0.001634 |
47 | ENDOPEPTIDASE ACTIVITY | 8 | 448 | 0.0001667 | 0.003295 |
48 | HEAT SHOCK PROTEIN BINDING | 4 | 89 | 0.0002685 | 0.005014 |
49 | KINASE INHIBITOR ACTIVITY | 4 | 89 | 0.0002685 | 0.005014 |
50 | CYCLIC NUCLEOTIDE BINDING | 3 | 36 | 0.0002699 | 0.005014 |
51 | PEPTIDASE ACTIVATOR ACTIVITY | 3 | 38 | 0.0003173 | 0.005779 |
52 | PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 5 | 178 | 0.0004002 | 0.00715 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | MEMBRANE MICRODOMAIN | 18 | 288 | 4.928e-18 | 2.878e-15 |
2 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 15 | 237 | 3.309e-15 | 7.623e-13 |
3 | CATALYTIC COMPLEX | 25 | 1038 | 3.916e-15 | 7.623e-13 |
4 | MEMBRANE PROTEIN COMPLEX | 23 | 1020 | 2.661e-13 | 3.885e-11 |
5 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 7 | 20 | 3.534e-13 | 4.127e-11 |
6 | TRANSFERASE COMPLEX | 16 | 703 | 1.938e-09 | 1.887e-07 |
7 | MEMBRANE REGION | 19 | 1134 | 7.168e-09 | 5.981e-07 |
8 | CILIARY BASE | 5 | 23 | 1.455e-08 | 1.062e-06 |
9 | PLASMA MEMBRANE PROTEIN COMPLEX | 13 | 510 | 2.085e-08 | 1.353e-06 |
10 | PROTEIN KINASE COMPLEX | 7 | 90 | 2.807e-08 | 1.639e-06 |
11 | CYTOSOLIC PART | 9 | 223 | 8.172e-08 | 4.339e-06 |
12 | MITOCHONDRION | 20 | 1633 | 4.697e-07 | 2.286e-05 |
13 | CD40 RECEPTOR COMPLEX | 3 | 11 | 6.64e-06 | 0.0002983 |
14 | RECEPTOR COMPLEX | 8 | 327 | 1.834e-05 | 0.0007649 |
15 | PHOSPHATASE COMPLEX | 4 | 48 | 2.383e-05 | 0.0009279 |
16 | EXTRINSIC COMPONENT OF MEMBRANE | 7 | 252 | 2.829e-05 | 0.001032 |
17 | OUTER MEMBRANE | 6 | 190 | 5.376e-05 | 0.001847 |
18 | MITOCHONDRIAL ENVELOPE | 10 | 691 | 0.0001386 | 0.004497 |
19 | PLASMA MEMBRANE RAFT | 4 | 86 | 0.0002354 | 0.007234 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04210_Apoptosis | 70 | 89 | 1.297e-182 | 2.296e-180 | |
2 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 21 | 136 | 1.773e-29 | 1.569e-27 | |
3 | hsa04620_Toll.like_receptor_signaling_pathway | 19 | 102 | 2.432e-28 | 1.241e-26 | |
4 | hsa04722_Neurotrophin_signaling_pathway | 20 | 127 | 2.964e-28 | 1.241e-26 | |
5 | hsa04380_Osteoclast_differentiation | 20 | 128 | 3.504e-28 | 1.241e-26 | |
6 | hsa04660_T_cell_receptor_signaling_pathway | 19 | 108 | 7.892e-28 | 2.328e-26 | |
7 | hsa04662_B_cell_receptor_signaling_pathway | 17 | 75 | 5.521e-27 | 1.396e-25 | |
8 | hsa04010_MAPK_signaling_pathway | 23 | 268 | 3.301e-26 | 7.305e-25 | |
9 | hsa04370_VEGF_signaling_pathway | 16 | 76 | 7.403e-25 | 1.456e-23 | |
10 | hsa04910_Insulin_signaling_pathway | 16 | 138 | 1.953e-20 | 3.457e-19 | |
11 | hsa04062_Chemokine_signaling_pathway | 15 | 189 | 1.118e-16 | 1.799e-15 | |
12 | hsa04914_Progesterone.mediated_oocyte_maturation | 12 | 87 | 1.81e-16 | 2.67e-15 | |
13 | hsa04510_Focal_adhesion | 15 | 200 | 2.621e-16 | 3.569e-15 | |
14 | hsa04115_p53_signaling_pathway | 11 | 69 | 6.591e-16 | 8.332e-15 | |
15 | hsa04973_Carbohydrate_digestion_and_absorption | 9 | 44 | 2.973e-14 | 3.508e-13 | |
16 | hsa04622_RIG.I.like_receptor_signaling_pathway | 10 | 71 | 5.506e-14 | 6.091e-13 | |
17 | hsa04150_mTOR_signaling_pathway | 9 | 52 | 1.509e-13 | 1.571e-12 | |
18 | hsa04664_Fc_epsilon_RI_signaling_pathway | 10 | 79 | 1.681e-13 | 1.653e-12 | |
19 | hsa04012_ErbB_signaling_pathway | 10 | 87 | 4.567e-13 | 4.254e-12 | |
20 | hsa04920_Adipocytokine_signaling_pathway | 9 | 68 | 1.935e-12 | 1.712e-11 | |
21 | hsa04630_Jak.STAT_signaling_pathway | 11 | 155 | 6.184e-12 | 5.212e-11 | |
22 | hsa04621_NOD.like_receptor_signaling_pathway | 8 | 59 | 2.868e-11 | 2.307e-10 | |
23 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 9 | 95 | 4.282e-11 | 3.295e-10 | |
24 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 7 | 42 | 1.157e-10 | 8.386e-10 | |
25 | hsa04720_Long.term_potentiation | 8 | 70 | 1.184e-10 | 8.386e-10 | |
26 | hsa04310_Wnt_signaling_pathway | 9 | 151 | 2.755e-09 | 1.875e-08 | |
27 | hsa04114_Oocyte_meiosis | 8 | 114 | 6.115e-09 | 4.008e-08 | |
28 | hsa04070_Phosphatidylinositol_signaling_system | 7 | 78 | 1.026e-08 | 6.487e-08 | |
29 | hsa04670_Leukocyte_transendothelial_migration | 7 | 117 | 1.73e-07 | 1.056e-06 | |
30 | hsa04020_Calcium_signaling_pathway | 8 | 177 | 1.9e-07 | 1.121e-06 | |
31 | hsa04810_Regulation_of_actin_cytoskeleton | 7 | 214 | 9.855e-06 | 5.627e-05 | |
32 | hsa04623_Cytosolic_DNA.sensing_pathway | 4 | 56 | 4.405e-05 | 0.0002437 | |
33 | hsa04360_Axon_guidance | 5 | 130 | 9.267e-05 | 0.0004971 | |
34 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 5 | 168 | 0.0003069 | 0.001598 | |
35 | hsa04962_Vasopressin.regulated_water_reabsorption | 3 | 44 | 0.0004906 | 0.002481 | |
36 | hsa04742_Taste_transduction | 3 | 52 | 0.0008025 | 0.003946 | |
37 | hsa04340_Hedgehog_signaling_pathway | 3 | 56 | 0.0009966 | 0.004767 | |
38 | hsa00562_Inositol_phosphate_metabolism | 3 | 57 | 0.001049 | 0.004888 | |
39 | hsa04976_Bile_secretion | 3 | 71 | 0.001979 | 0.008983 | |
40 | hsa04971_Gastric_acid_secretion | 3 | 74 | 0.002228 | 0.009859 | |
41 | hsa04970_Salivary_secretion | 3 | 89 | 0.00376 | 0.01623 | |
42 | hsa04540_Gap_junction | 3 | 90 | 0.00388 | 0.01635 | |
43 | hsa04912_GnRH_signaling_pathway | 3 | 101 | 0.005356 | 0.02155 | |
44 | hsa04916_Melanogenesis | 3 | 101 | 0.005356 | 0.02155 | |
45 | hsa04270_Vascular_smooth_muscle_contraction | 3 | 116 | 0.007848 | 0.03087 | |
46 | hsa04120_Ubiquitin_mediated_proteolysis | 3 | 139 | 0.01281 | 0.0493 | |
47 | hsa04640_Hematopoietic_cell_lineage | 2 | 88 | 0.03811 | 0.1435 | |
48 | hsa04110_Cell_cycle | 2 | 128 | 0.07408 | 0.2732 | |
49 | hsa04530_Tight_junction | 2 | 133 | 0.07913 | 0.2858 | |
50 | hsa04740_Olfactory_transduction | 3 | 388 | 0.1547 | 0.5475 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | HCG11 |
hsa-miR-106b-5p;hsa-miR-107;hsa-miR-122-5p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-362-5p;hsa-miR-421;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-93-5p | 14 | AKT3 | Sponge network | -0.781 | 0 | -0.659 | 0.00047 | 0.574 |
2 | HCG11 |
hsa-miR-103a-3p;hsa-miR-130b-5p;hsa-miR-148a-3p;hsa-miR-15a-5p;hsa-miR-15b-3p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-20a-3p;hsa-miR-20a-5p;hsa-miR-455-5p;hsa-miR-618 | 12 | BCL2 | Sponge network | -0.781 | 0 | -0.346 | 0.02497 | 0.56 |
3 | DHRS4-AS1 |
hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-582-5p;hsa-miR-589-3p | 10 | PIK3R1 | Sponge network | -0.646 | 0.01829 | -0.892 | 0 | 0.557 |
4 | HCG11 |
hsa-miR-130b-3p;hsa-miR-16-1-3p;hsa-miR-192-5p;hsa-miR-193a-3p;hsa-miR-193b-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-224-3p;hsa-miR-301a-3p;hsa-miR-362-3p | 11 | ENDOD1 | Sponge network | -0.781 | 0 | -0.999 | 0 | 0.544 |
5 | DNM3OS |
hsa-miR-106b-5p;hsa-miR-107;hsa-miR-122-5p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-32-3p;hsa-miR-502-3p;hsa-miR-616-5p;hsa-miR-93-5p | 11 | AKT3 | Sponge network | -2.094 | 1.0E-5 | -0.659 | 0.00047 | 0.541 |
6 | RP11-434D9.1 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-199b-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-409-3p;hsa-miR-429;hsa-miR-629-3p | 17 | PIK3R1 | Sponge network | -2.913 | 0 | -0.892 | 0 | 0.525 |
7 | LINC00261 |
hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-15b-5p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-330-3p;hsa-miR-589-3p;hsa-miR-629-3p | 15 | PIK3R1 | Sponge network | -1.194 | 0 | -0.892 | 0 | 0.513 |
8 | RP11-252E2.2 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-199b-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -5.878 | 0 | -0.892 | 0 | 0.505 |
9 | RP4-539M6.20 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-218-5p;hsa-miR-324-3p;hsa-miR-495-3p | 11 | PIK3R1 | Sponge network | -1.177 | 0.00034 | -0.892 | 0 | 0.493 |
10 | RP11-513G11.3 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-199b-5p;hsa-miR-200b-3p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-93-5p | 14 | PIK3R1 | Sponge network | -2.342 | 5.0E-5 | -0.892 | 0 | 0.492 |
11 | RP11-12A2.3 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-199b-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-485-3p;hsa-miR-93-5p | 18 | PIK3R1 | Sponge network | -4.779 | 0 | -0.892 | 0 | 0.489 |
12 | LIPE-AS1 |
hsa-miR-103a-3p;hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-127-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-338-5p;hsa-miR-589-3p;hsa-miR-654-3p;hsa-miR-93-5p | 17 | PIK3R1 | Sponge network | -0.323 | 0.03968 | -0.892 | 0 | 0.488 |
13 | AC004160.4 | hsa-miR-106b-5p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p | 10 | PIK3R1 | Sponge network | -6.232 | 0 | -0.892 | 0 | 0.477 |
14 | LINC01018 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-338-5p;hsa-miR-409-3p;hsa-miR-589-3p;hsa-miR-629-3p;hsa-miR-93-5p | 20 | PIK3R1 | Sponge network | -3.231 | 0 | -0.892 | 0 | 0.472 |
15 | AJ006998.2 | hsa-miR-127-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-182-5p;hsa-miR-199b-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-409-3p | 10 | PIK3R1 | Sponge network | 0.13 | 0.84524 | -0.892 | 0 | 0.453 |
16 | LDLRAD4-AS1 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-589-3p;hsa-miR-93-5p | 15 | PIK3R1 | Sponge network | -3.366 | 0 | -0.892 | 0 | 0.45 |
17 | RP11-166D19.1 |
hsa-miR-103a-3p;hsa-miR-130b-5p;hsa-miR-15a-5p;hsa-miR-15b-3p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-20a-3p;hsa-miR-20a-5p;hsa-miR-32-3p;hsa-miR-33a-5p;hsa-miR-590-5p;hsa-miR-616-5p;hsa-miR-618 | 14 | BCL2 | Sponge network | -0.244 | 0.28835 | -0.346 | 0.02497 | 0.449 |
18 | RP11-104J23.1 |
hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-182-5p;hsa-miR-199b-5p;hsa-miR-200b-3p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p | 10 | PIK3R1 | Sponge network | -1.195 | 0.00749 | -0.892 | 0 | 0.447 |
19 | RP11-7M8.2 | hsa-miR-106a-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-493-5p | 11 | PIK3R1 | Sponge network | -1.367 | 0.138 | -0.892 | 0 | 0.444 |
20 | AC005550.3 |
hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-27a-3p;hsa-miR-342-3p;hsa-miR-501-3p | 13 | PPP3R1 | Sponge network | -2.571 | 0.00132 | -0.348 | 0 | 0.423 |
21 | RP11-119D9.1 |
hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-199b-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p;hsa-miR-93-5p | 15 | PIK3R1 | Sponge network | -2.765 | 0 | -0.892 | 0 | 0.418 |
22 | RP11-115C10.1 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-127-5p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-429 | 11 | PIK3R1 | Sponge network | -2.686 | 0.00069 | -0.892 | 0 | 0.409 |
23 | RP5-834N19.1 | hsa-miR-106b-5p;hsa-miR-132-3p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -1.722 | 0.00283 | -0.892 | 0 | 0.408 |
24 | RP11-290F5.1 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-485-3p;hsa-miR-493-5p | 17 | PIK3R1 | Sponge network | -1.679 | 5.0E-5 | -0.892 | 0 | 0.402 |
25 | RP11-42O15.3 | hsa-miR-106b-5p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-199b-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-218-5p;hsa-miR-429 | 10 | PIK3R1 | Sponge network | -1.562 | 0 | -0.892 | 0 | 0.397 |
26 | RP11-12A2.3 |
hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-27a-3p;hsa-miR-335-3p;hsa-miR-501-3p;hsa-miR-93-5p | 15 | PPP3R1 | Sponge network | -4.779 | 0 | -0.348 | 0 | 0.397 |
27 | RP11-119D9.1 |
hsa-miR-106b-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-188-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-24-3p;hsa-miR-27a-3p;hsa-miR-335-3p;hsa-miR-342-3p;hsa-miR-501-3p;hsa-miR-93-5p;hsa-miR-940 | 16 | PPP3R1 | Sponge network | -2.765 | 0 | -0.348 | 0 | 0.395 |
28 | TPRG1-AS1 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-199b-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-218-5p;hsa-miR-409-3p;hsa-miR-629-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -0.756 | 0.03021 | -0.892 | 0 | 0.394 |
29 | DNM3OS |
hsa-miR-103a-3p;hsa-miR-130b-5p;hsa-miR-148a-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-20a-5p;hsa-miR-32-3p;hsa-miR-590-5p;hsa-miR-616-5p;hsa-miR-618 | 11 | BCL2 | Sponge network | -2.094 | 1.0E-5 | -0.346 | 0.02497 | 0.391 |
30 | MIR22HG |
hsa-miR-103a-3p;hsa-miR-130b-5p;hsa-miR-15b-3p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-20a-3p;hsa-miR-20a-5p;hsa-miR-32-3p;hsa-miR-590-5p;hsa-miR-618 | 10 | BCL2 | Sponge network | -0.234 | 0.09523 | -0.346 | 0.02497 | 0.382 |
31 | RP11-115J16.1 | hsa-miR-103a-3p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-200b-3p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-338-5p;hsa-miR-589-3p;hsa-miR-93-5p | 14 | PIK3R1 | Sponge network | -2.038 | 7.0E-5 | -0.892 | 0 | 0.382 |
32 | MAGI2-AS3 |
hsa-miR-188-5p;hsa-miR-20a-3p;hsa-miR-224-3p;hsa-miR-25-3p;hsa-miR-324-5p;hsa-miR-421;hsa-miR-452-3p;hsa-miR-589-3p;hsa-miR-616-5p;hsa-miR-660-5p;hsa-miR-92a-3p | 11 | IRAK3 | Sponge network | -1.801 | 0 | -1.135 | 0 | 0.377 |
33 | RP11-545I5.3 |
hsa-miR-127-5p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-409-3p;hsa-miR-485-3p;hsa-miR-493-5p;hsa-miR-495-3p;hsa-miR-582-5p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-93-5p | 13 | PIK3R1 | Sponge network | 0.139 | 0.66524 | -0.892 | 0 | 0.377 |
34 | LINC00238 |
hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-27a-3p;hsa-miR-342-3p | 13 | PPP3R1 | Sponge network | -4.997 | 0 | -0.348 | 0 | 0.375 |
35 | CTD-2194A8.2 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-218-5p;hsa-miR-330-3p;hsa-miR-485-3p;hsa-miR-495-3p;hsa-miR-654-3p | 12 | PIK3R1 | Sponge network | -0.829 | 0.11289 | -0.892 | 0 | 0.375 |
36 | LINC00238 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-199b-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p | 16 | PIK3R1 | Sponge network | -4.997 | 0 | -0.892 | 0 | 0.369 |
37 | AC004862.6 |
hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-27a-3p;hsa-miR-335-3p;hsa-miR-93-5p | 14 | PPP3R1 | Sponge network | -2.202 | 0.00081 | -0.348 | 0 | 0.365 |
38 | MAGI2-AS3 |
hsa-miR-106b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-30d-5p;hsa-miR-589-3p;hsa-miR-616-5p;hsa-miR-93-3p;hsa-miR-93-5p | 10 | PPP3CA | Sponge network | -1.801 | 0 | -0.536 | 0 | 0.362 |
39 | RP11-473I1.9 | hsa-miR-107;hsa-miR-122-5p;hsa-miR-146b-5p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-33a-3p;hsa-miR-362-5p;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-616-5p;hsa-miR-93-5p | 12 | AKT3 | Sponge network | -0.126 | 0.22247 | -0.659 | 0.00047 | 0.36 |
40 | AC004862.6 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-199b-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-589-3p;hsa-miR-629-3p;hsa-miR-93-5p | 17 | PIK3R1 | Sponge network | -2.202 | 0.00081 | -0.892 | 0 | 0.357 |
41 | RP11-250B2.6 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-199b-5p;hsa-miR-200b-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-93-5p | 15 | PIK3R1 | Sponge network | -0.98 | 2.0E-5 | -0.892 | 0 | 0.342 |
42 | AP000473.5 |
hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-338-5p | 12 | PIK3R1 | Sponge network | -1.157 | 0.00884 | -0.892 | 0 | 0.341 |
43 | BDNF-AS | hsa-miR-106a-5p;hsa-miR-127-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-369-3p;hsa-miR-409-3p;hsa-miR-495-3p;hsa-miR-629-3p | 13 | PIK3R1 | Sponge network | 0.214 | 0.16872 | -0.892 | 0 | 0.338 |
44 | RP11-250B2.6 |
hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-27a-3p;hsa-miR-93-5p | 13 | PPP3R1 | Sponge network | -0.98 | 2.0E-5 | -0.348 | 0 | 0.333 |
45 | RP11-736K20.5 | hsa-miR-103a-3p;hsa-miR-127-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-185-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-409-3p;hsa-miR-485-3p;hsa-miR-629-3p | 12 | PIK3R1 | Sponge network | -0.26 | 0.20252 | -0.892 | 0 | 0.33 |
46 | RP11-963H4.3 | hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-21-5p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -1.857 | 0.00116 | -0.892 | 0 | 0.328 |
47 | LIPE-AS1 |
hsa-miR-106b-5p;hsa-miR-143-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-93-5p | 12 | PPP3R1 | Sponge network | -0.323 | 0.03968 | -0.348 | 0 | 0.327 |
48 | RP11-407B7.1 |
hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-199b-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-338-5p;hsa-miR-369-3p;hsa-miR-429;hsa-miR-493-5p;hsa-miR-582-5p;hsa-miR-629-3p;hsa-miR-93-5p | 21 | PIK3R1 | Sponge network | -0.818 | 0.00584 | -0.892 | 0 | 0.324 |
49 | LINC00864 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-15b-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -3.954 | 0 | -0.892 | 0 | 0.322 |
50 | MAGI2-AS3 |
hsa-miR-106b-5p;hsa-miR-107;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-362-3p;hsa-miR-362-5p;hsa-miR-421;hsa-miR-616-5p;hsa-miR-93-5p | 10 | AKT3 | Sponge network | -1.801 | 0 | -0.659 | 0.00047 | 0.322 |
51 | RP11-372E1.4 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-182-5p;hsa-miR-199b-5p;hsa-miR-200b-3p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-338-5p;hsa-miR-409-3p;hsa-miR-93-5p | 12 | PIK3R1 | Sponge network | -0.887 | 0.1067 | -0.892 | 0 | 0.321 |
52 | RP11-12A2.3 |
hsa-miR-141-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-339-5p;hsa-miR-93-5p | 12 | PRKACB | Sponge network | -4.779 | 0 | -0.44 | 6.0E-5 | 0.321 |
53 | RP11-166D19.1 |
hsa-miR-103a-3p;hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-222-3p;hsa-miR-324-3p;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-629-3p | 15 | PIK3R1 | Sponge network | -0.244 | 0.28835 | -0.892 | 0 | 0.32 |
54 | LINC00261 |
hsa-miR-106b-5p;hsa-miR-143-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-188-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-27a-3p;hsa-miR-940 | 12 | PPP3R1 | Sponge network | -1.194 | 0 | -0.348 | 0 | 0.319 |
55 | RP11-513G11.3 |
hsa-miR-106b-5p;hsa-miR-143-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-27a-3p;hsa-miR-93-5p | 12 | PPP3R1 | Sponge network | -2.342 | 5.0E-5 | -0.348 | 0 | 0.318 |
56 | LDLRAD4-AS1 |
hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-93-5p | 11 | PPP3R1 | Sponge network | -3.366 | 0 | -0.348 | 0 | 0.311 |
57 | RP13-650J16.1 | hsa-miR-106b-5p;hsa-miR-127-5p;hsa-miR-132-3p;hsa-miR-182-5p;hsa-miR-199b-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-495-3p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -0.901 | 0.04097 | -0.892 | 0 | 0.311 |
58 | RP11-1018N14.5 | hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-409-3p;hsa-miR-93-5p | 10 | PIK3R1 | Sponge network | -0.573 | 0.20573 | -0.892 | 0 | 0.31 |
59 | LINC01018 |
hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-335-3p;hsa-miR-93-5p | 13 | PPP3R1 | Sponge network | -3.231 | 0 | -0.348 | 0 | 0.309 |
60 | RP11-736K20.6 | hsa-miR-103a-3p;hsa-miR-127-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-199b-5p;hsa-miR-200b-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-485-3p;hsa-miR-629-3p | 14 | PIK3R1 | Sponge network | -0.197 | 0.37494 | -0.892 | 0 | 0.305 |
61 | MAGI2-AS3 |
hsa-miR-130b-3p;hsa-miR-192-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-224-3p;hsa-miR-301a-3p;hsa-miR-362-3p;hsa-miR-589-3p;hsa-miR-589-5p | 11 | ENDOD1 | Sponge network | -1.801 | 0 | -0.999 | 0 | 0.301 |
62 | RP11-166D19.1 |
hsa-miR-130b-3p;hsa-miR-16-1-3p;hsa-miR-192-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-301a-3p;hsa-miR-361-5p;hsa-miR-3613-5p;hsa-miR-589-3p;hsa-miR-589-5p | 12 | ENDOD1 | Sponge network | -0.244 | 0.28835 | -0.999 | 0 | 0.301 |
63 | LINC00885 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p | 10 | PIK3R1 | Sponge network | -4.686 | 0 | -0.892 | 0 | 0.3 |
64 | RP11-43F13.3 | hsa-miR-103a-3p;hsa-miR-130b-5p;hsa-miR-148a-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-204-5p;hsa-miR-20a-5p;hsa-miR-32-3p;hsa-miR-365a-3p;hsa-miR-455-5p;hsa-miR-616-5p | 12 | BCL2 | Sponge network | -1.507 | 0.01021 | -0.346 | 0.02497 | 0.295 |
65 | MAGI2-AS3 |
hsa-miR-103a-3p;hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-589-3p;hsa-miR-629-3p;hsa-miR-93-5p | 15 | PIK3R1 | Sponge network | -1.801 | 0 | -0.892 | 0 | 0.294 |
66 | RP11-538D16.2 | hsa-miR-127-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-199b-5p;hsa-miR-200b-3p;hsa-miR-21-5p;hsa-miR-218-5p;hsa-miR-222-3p;hsa-miR-338-5p;hsa-miR-369-3p;hsa-miR-409-3p;hsa-miR-629-3p;hsa-miR-654-3p | 15 | PIK3R1 | Sponge network | 0.603 | 0.33218 | -0.892 | 0 | 0.292 |
67 | DHRS4-AS1 |
hsa-miR-106b-5p;hsa-miR-140-3p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-589-3p | 10 | XIAP | Sponge network | -0.646 | 0.01829 | -0.153 | 0.0753 | 0.292 |
68 | RP11-166D19.1 |
hsa-miR-16-1-3p;hsa-miR-188-5p;hsa-miR-20a-3p;hsa-miR-25-3p;hsa-miR-32-5p;hsa-miR-33a-5p;hsa-miR-361-5p;hsa-miR-421;hsa-miR-589-3p;hsa-miR-590-5p;hsa-miR-616-5p;hsa-miR-92a-3p | 12 | IRAK3 | Sponge network | -0.244 | 0.28835 | -1.135 | 0 | 0.29 |
69 | LINC00675 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-221-3p;hsa-miR-222-3p | 10 | PIK3R1 | Sponge network | -2.286 | 0.00023 | -0.892 | 0 | 0.288 |
70 | AP000473.5 |
hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p | 10 | PPP3R1 | Sponge network | -1.157 | 0.00884 | -0.348 | 0 | 0.283 |
71 | AC005550.3 |
hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-199b-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p | 13 | PIK3R1 | Sponge network | -2.571 | 0.00132 | -0.892 | 0 | 0.281 |
72 | RP11-7F17.3 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-324-3p | 13 | PIK3R1 | Sponge network | -0.873 | 0.00204 | -0.892 | 0 | 0.271 |
73 | SMIM2-AS1 |
hsa-miR-103a-3p;hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-127-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-188-5p;hsa-miR-199b-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-369-3p;hsa-miR-409-3p;hsa-miR-589-3p;hsa-miR-629-3p | 21 | PIK3R1 | Sponge network | -0.66 | 0.00587 | -0.892 | 0 | 0.27 |
74 | AC068138.1 |
hsa-miR-143-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-20a-5p;hsa-miR-24-3p;hsa-miR-27a-3p;hsa-miR-335-3p | 11 | PPP3R1 | Sponge network | 2.041 | 0.0022 | -0.348 | 0 | 0.27 |
75 | RP11-143N13.2 | hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-182-5p;hsa-miR-21-5p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-485-3p;hsa-miR-495-3p;hsa-miR-654-3p | 12 | PIK3R1 | Sponge network | -1.036 | 0.08988 | -0.892 | 0 | 0.269 |
76 | RP11-104J23.1 |
hsa-miR-143-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-24-3p;hsa-miR-27a-3p;hsa-miR-335-3p | 11 | PPP3R1 | Sponge network | -1.195 | 0.00749 | -0.348 | 0 | 0.267 |
77 | RP11-7F17.3 |
hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-181a-5p;hsa-miR-181b-5p;hsa-miR-181c-5p;hsa-miR-181d-5p;hsa-miR-183-5p;hsa-miR-188-5p;hsa-miR-20a-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-501-3p;hsa-miR-940 | 13 | PPP3R1 | Sponge network | -0.873 | 0.00204 | -0.348 | 0 | 0.263 |
78 | RP4-594I10.3 | hsa-miR-106b-5p;hsa-miR-1301-3p;hsa-miR-132-3p;hsa-miR-182-5p;hsa-miR-21-5p;hsa-miR-212-3p;hsa-miR-218-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-629-3p;hsa-miR-93-5p | 11 | PIK3R1 | Sponge network | -2.333 | 0.00136 | -0.892 | 0 | 0.253 |